Elevated	O
cyclic	O
AMP	O
inhibits	O
NF-kappaB	B-protein
-mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O

The	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
,	O
tissue	B-protein
factor	I-protein
,	O
endothelial	B-protein
leukocyte	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
genes	I-DNA
.	O

Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	B-protein
and	O
tissue	B-protein
factor	I-protein
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Induction	O
of	O
NF-kappaB	B-protein
-dependent	O
gene	O
expression	O
in	O
transiently	O
transfected	O
human	B-cell_line
monocytic	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
elevated	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
.	O

Elevated	O
cAMP	O
did	O
not	O
prevent	O
nuclear	O
translocation	O
of	O
p50/p65	B-protein
and	O
c-Rel/p65	B-protein
heterodimers	I-protein
,	O
decrease	O
nuclear	O
translocation	O
of	O
p65	B-protein
,	O
or	O
significantly	O
modify	O
TNFalpha	B-protein
-induced	O
phosphorylation	O
of	O
p65	B-protein
.	O

Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	B-DNA
containing	O
multimerized	B-DNA
kappaB	I-DNA
sites	I-DNA
by	O
p65	B-protein
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
PKA	B-protein
.	O

This	O
study	O
indicates	O
that	O
activation	O
of	O
PKA	B-protein
reduces	O
the	O
induction	O
of	O
a	O
distinct	O
set	O
of	O
genes	B-DNA
in	O
monocytes	B-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
by	O
inhibiting	O
NF-kappaB	B-protein
-mediated	O
transcription	O
.	O

THz	NULL
JourNat	NULL
or	NULL
BioLoGIcaL	NULL
CHEMISTRY	NULL
©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

271	NULL
,	NULL
No	NULL
.	NULL

34	NULL
,	NULL
Issue	NULL
of	NULL
August	NULL
23	NULL
,	NULL
pp	NULL
.	NULL

20828-20835	NULL
,	NULL
1996	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Elevated	NULL
Cyclic	NULL
AMP	NULL
Inhibits	NULL
NF-	NULL
«	NULL
-B-mediated	NULL
Transcription	NULL
in	NULL
Human	NULL
Monocytic	NULL
Cells	NULL
and	NULL
Endothelial	NULL
Cells*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
March	NULL
18	NULL
,	NULL
1996	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
June	NULL
3	NULL
,	NULL
1996	NULL
)	NULL
Veronique	NULL
Ollivier	NULL
#	NULL
§	NULL
(	NULL
|	NULL
,	NULL
Graham	NULL
C.	NULL
N.	NULL
Parry	NULL
#	NULL
(	NULL
,	NULL
Ronald	NULL
R.	NULL
Cobb**|	NULL
,	NULL
Dominique	NULL
de	NULL
Prost	NULL
?	NULL

$	NULL
,	NULL
and	NULL
Nigel	NULL
Mackmant§§	NULL
From	NULL
the	NULL
{	NULL
Departments	NULL
of	NULL
Immunology	NULL
and	NULL
Vascular	NULL
Biology	NULL
,	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
California	NULL
92037	NULL
,	NULL
the	NULL
**\Department	NULL
of	NULL
Biology	NULL
,	NULL
Tanabe	NULL
Research	NULL
Laboratories	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
California	NULL
92121	NULL
,	NULL
and	NULL
$	NULL
fINSERM	NULL
U294	NULL
and	NULL
Service	NULL
d'Hematologie	NULL
et	NULL
d'Immunologie	NULL
Biologiques	NULL
,	NULL
Chu	NULL
Xavier	NULL
Bichat	NULL
,	NULL
46	NULL
,	NULL
rue	NULL
Henri	NULL
Huchard	NULL
,	NULL
75877	NULL
Paris	NULL
Cedex	NULL
18	NULL
,	NULL
France	NULL
The	NULL
NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
regulates	NULL
the	NULL
inducible	NULL
expression	NULL
of	NULL
many	NULL
genes	NULL
in	NULL
activated	NULL
human	NULL
monocytes	NULL
and	NULL
endothelial	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
molecular	NULL
mechanism	NULL
by	NULL
which	NULL
agents	NULL
that	NULL
elevate	NULL
intracellular	NULL
cAMP	NULL
inhibit	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
TNFa	NULL
)	NULL
,	NULL
tissue	NULL
factor	NULL
,	NULL
endothelial	NULL
leukocyte	NULL
adhesion	NULL
molecule-1	NULL
,	NULL
and	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
genes	NULL
.	NULL

Both	NULL
forskolin	NULL
and	NULL
dibutyryl	NULL
cAMP	NULL
,	NULL
which	NULL
elevate	NULL
intracellular	NULL
cAMP	NULL
by	NULL
independent	NULL
mechanisms	NULL
,	NULL
inhibited	NULL
TNFa	NULL
and	NULL
tissue	NULL
factor	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
.	NULL

Induction	NULL
of	NULL
NF-	NULL
«	NULL
B-dependent	NULL
gene	NULL
expression	NULL
in	NULL
transiently	NULL
transfected	NULL
human	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
and	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
elevated	NULL
cAMP	NULL
and	NULL
by	NULL
overexpression	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
.	NULL

Elevated	NULL
cAMP	NULL
did	NULL
not	NULL
prevent	NULL
nuclear	NULL
translocation	NULL
of	NULL
p50/p65	NULL
and	NULL
c-Rel/p65	NULL
heterodimers	NULL
,	NULL
decrease	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
,	NULL
or	NULL
significantly	NULL
modify	NULL
TNFa-induced	NULL
phosphorylation	NULL
of	NULL
p65	NULL
.	NULL

Functional	NULL
studies	NULL
demonstrated	NULL
that	NULL
transcriptional	NULL
activation	NULL
of	NULL
a	NULL
plasmid	NULL
containing	NULL
multimerized	NULL
«	NULL
B	NULL
sites	NULL
by	NULL
p65	NULL
was	NULL
inhibited	NULL
by	NULL
agents	NULL
that	NULL
elevate	NULL
cAMP	NULL
and	NULL
by	NULL
overexpression	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
.	NULL

This	NULL
study	NULL
indicates	NULL
that	NULL
activation	NULL
of	NULL
PKA	NULL
reduces	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
distinct	NULL
set	NULL
of	NULL
genes	NULL
in	NULL
monocytes	NULL
and	NULL
endothelial	NULL
cells	NULL
by	NULL
inhibiting	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
.	NULL

Human	NULL
monocytes	NULL
and	NULL
endothelial	NULL
cells	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
express	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
,	NULL
cell	NULL
adhesion	NULL
,	NULL
blood	NULL
coagulation	NULL
,	NULL
and	NULL
fibrinoly-sis	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
bacterial	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
HL16411	NULL
and	NULL
HL48872	NULL
(	NULL
to	NULL
N.	NULL
M.	NULL
)	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
Present	NULL
address	NULL
:	NULL
INSERM	NULL
U294	NULL
and	NULL
Service	NULL
d'Hematologie	NULL
et	NULL
d'Immunologie	NULL
Biologiques	NULL
,	NULL
Chu	NULL
Xavier	NULL
Bichat	NULL
,	NULL
46	NULL
,	NULL
rue	NULL
Henri	NULL
Huchard	NULL
,	NULL
75877	NULL
Paris	NULL
Cedex	NULL
18	NULL
,	NULL
France	NULL
.	NULL

4	NULL
Contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

|	NULL
Supported	NULL
by	NULL
a	NULL
scholarship	NULL
from	NULL
the	NULL
Sanofi	NULL
Association	NULL
for	NULL
Thrombosis	NULL
Research	NULL
.	NULL

§§Performed	NULL
this	NULL
work	NULL
during	NULL
the	NULL
tenure	NULL
of	NULL
an	NULL
Established	NULL
Investi-gatorship	NULL
from	NULL
the	NULL
American	NULL
Heart	NULL
Association	NULL
.	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Depts	NULL
.	NULL

of	NULL
Immunology	NULL
and	NULL
Vascular	NULL
Biology	NULL
,	NULL
Scripps	NULL
Research	NULL
Inst	NULL
.	NULL

,	NULL
10666	NULL
N.	NULL
Torrey	NULL
Pines	NULL
Rd	NULL
.	NULL

,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
92037	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
619-554-8594	NULL
;	NULL
Fax	NULL
:	NULL
619-554-6146	NULL
;	NULL
E-mail	NULL
:	NULL
nmackman	NULL
@	NULL
scripps.edu	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
LPS	NULL
,	NULL
lipopolysaccharide	NULL
;	NULL
TNF	NULL
#	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
;	NULL
TF	NULL
,	NULL
tissue	NULL
factor	NULL
;	NULL
E-selectin	NULL
,	NULL
endothelial	NULL
leukocyte	NULL
adhesion	NULL
molecule-1	NULL
;	NULL
VCAM-1	NULL
,	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
;	NULL
ICAM-1	NULL
,	NULL
intercellular	NULL
adhesion	NULL
molecule-1	NULL
;	NULL
PKA	NULL
,	NULL
protein	NULL
kinase	NULL
A	NULL
;	NULL
stimulates	NULL
monocytic	NULL
cells	NULL
to	NULL
rapidly	NULL
and	NULL
transiently	NULL
express	NULL
a	NULL
defined	NULL
set	NULL
of	NULL
gene	NULL
products	NULL
including	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
(	NULL
TNFa	NULL
)	NULL
(	NULL
3	NULL
)	NULL
and	NULL
the	NULL
transmembrane	NULL
receptor	NULL
tissue	NULL
factor	NULL
(	NULL
TF	NULL
)	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

In	NULL
endothelial	NULL
cells	NULL
,	NULL
LPS	NULL
and	NULL
cytokines	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
various	NULL
adhesion	NULL
molecules	NULL
,	NULL
including	NULL
endothelial	NULL
leukocyte	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
E-selectin	NULL
)	NULL
,	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
VCAM-1	NULL
)	NULL
,	NULL
and	NULL
intercellular	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
ICAM-1	NULL
)	NULL
,	NULL
which	NULL
permit	NULL
binding	NULL
and	NULL
transmigration	NULL
of	NULL
leukocytes	NULL
into	NULL
sites	NULL
of	NULL
inflammation	NULL
(	NULL
6-8	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
endothelial	NULL
cells	NULL
also	NULL
induces	NULL
TF	NULL
expression	NULL
,	NULL
which	NULL
converts	NULL
the	NULL
normal	NULL
anticoagulant	NULL
surface	NULL
to	NULL
a	NULL
procoagulant	NULL
state	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
inducible	NULL
expression	NULL
of	NULL
many	NULL
genes	NULL
in	NULL
monocytes	NULL
and	NULL
endothelial	NULL
cells	NULL
,	NULL
including	NULL
TNFa	NULL
,	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
(	NULL
12-15	NULL
)	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

l	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
includes	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
NFKB2	NULL
(	NULL
p52	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
RelB	NULL
,	NULL
and	NULL
c-Rel	NULL
(	NULL
16	NULL
)	NULL
.	NULL

These	NULL
factors	NULL
can	NULL
homo-	NULL
and	NULL
heterodimerize	NULL
to	NULL
generate	NULL
distinct	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
expression	NULL
of	NULL
many	NULL
different	NULL
genes	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
TNFa	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
genes	NULL
are	NULL
regulated	NULL
by	NULL
p50/p65	NULL
heterodimers	NULL
(	NULL
17	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
TF	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
c-Rel/p65	NULL
heterodimers	NULL
(	NULL
18	NULL
)	NULL
.	NULL

In	NULL
monocytes	NULL
and	NULL
endothelial	NULL
cells	NULL
,	NULL
LPS	NULL
and	NULL
cytokines	NULL
induce	NULL
the	NULL
dissociation	NULL
of	NULL
the	NULL
inhibitory	NULL
protein	NULL
IxBa	NULL
from	NULL
pre-existing	NULL
cytoplasmic	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
Rel	NULL
complexes	NULL
,	NULL
allowing	NULL
the	NULL
transcription	NULL
factors	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
initiate	NULL
expression	NULL
of	NULL
target	NULL
genes	NULL
(	NULL
19	NULL
)	NULL
.	NULL

cAMP	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
numerous	NULL
genes	NULL
through	NULL
the	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
mediated	NULL
phosphorylation	NULL
of	NULL
CRE-binding	NULL
factors	NULL
,	NULL
including	NULL
CRE-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Elevation	NULL
of	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
in	NULL
monocytes	NULL
and	NULL
endothelial	NULL
cells	NULL
also	NULL
inhibits	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
distinct	NULL
set	NULL
of	NULL
genes	NULL
,	NULL
including	NULL
TNFa	NULL
,	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
(	NULL
21-25	NULL
)	NULL
.	NULL

We	NULL
(	NULL
27	NULL
)	NULL
and	NULL
others	NULL
(	NULL
26	NULL
,	NULL
28	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
pharmacologic	NULL
agents	NULL
that	NULL
elevate	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
,	NULL
such	NULL
as	NULL
pentoxifylline	NULL
and	NULL
a	NULL
prostacyclin	NULL
analog	NULL
,	NULL
iloprost	NULL
,	NULL
inhibit	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
agents	NULL
such	NULL
as	NULL
dibutyryl	NULL
cAMP	NULL
(	NULL
Bt	NULL
,	NULL
cAMP	NULL
)	NULL
,	NULL
forskolin	NULL
,	NULL
and	NULL
isobutylmethylxan-thine	NULL
,	NULL
which	NULL
increase	NULL
cAMP	NULL
levels	NULL
by	NULL
independent	NULL
mechanisms	NULL
,	NULL
all	NULL
inhibit	NULL
induction	NULL
of	NULL
TF	NULL
expression	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

In	NULL
endothelial	NULL
cells	NULL
,	NULL
elevation	NULL
of	NULL
cAMP	NULL
and	NULL
activation	NULL
of	NULL
PKA	NULL
inhibit	NULL
cytokine	NULL
induction	NULL
of	NULL
E-selectin	NULL
,	NULL
VCAM-1	NULL
,	NULL
and	NULL
TF	NULL
expression	NULL
(	NULL
21	NULL
,	NULL
22	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Studies	NULL
using	NULL
both	NULL
monocytes	NULL
and	NULL
endothelial	NULL
cells	NULL
indicate	NULL
that	NULL
cAMP	NULL
inhibits	NULL
transcription	NULL
of	NULL
this	NULL
distinct	NULL
set	NULL
of	NULL
genes	NULL
(	NULL
21	NULL
,	NULL
23	NULL
,	NULL
25	NULL
,	NULL
30	NULL
)	NULL
.	NULL

This	NULL
study	NULL
examined	NULL
inhibition	NULL
of	NULL
the	NULL
transcriptional	NULL
activa-	NULL
tion	NULL
of	NULL
the	NULL
TNFa	NULL
,	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
genes	NULL
in	NULL
human	NULL
CRE	NULL
,	NULL
cAMP	NULL
response	NULL
element	NULL
;	NULL
Bt	NULL
,	NULL
cAMP	NULL
,	NULL
dibutyryl	NULL
cAMP	NULL
;	NULL
HUVECs	NULL
,	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyl-transferase	NULL
;	NULL
TA	NULL
,	NULL
transactivation	NULL
;	NULL
CREB	NULL
,	NULL
CRE-binding	NULL
protein	NULL
.	NULL

20828	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Cyclic	NULL
AMP	NULL
Inhibition	NULL
of	NULL
Transcription	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
by	NULL
agents	NULL
that	NULL
elevate	NULL
intracel-	NULL
lular	NULL
levels	NULL
of	NULL
cAMP	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Chemicals-LPS	NULL
(	NULL
Escherichia	NULL
coli	NULL
serotype	NULL
O111	NULL
:	NULL
B4	NULL
)	NULL
and	NULL
forskolin	NULL
were	NULL
purchased	NULL
from	NULL
Calbiochem	NULL
.	NULL

Bt	NULL
,	NULL
cAMP	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

Human	NULL
recombinant	NULL
TNFa	NULL
was	NULL
obtained	NULL
from	NULL
Collaborative	NULL
Biomedical	NULL
Products	NULL
(	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Cell	NULL
Culture-Human	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
cultured	NULL
as	NULL
described	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Primary	NULL
cultures	NULL
of	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
(	NULL
HUVECs	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
collagenase-digested	NULL
umbilical	NULL
veins	NULL
or	NULL
from	NULL
Clonetics	NULL
Corp.	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
were	NULL
cultured	NULL
as	NULL
described	NULL
(	NULL
11	NULL
)	NULL
.	NULL

All	NULL
experiments	NULL
used	NULL
HUVECs	NULL
between	NULL
passages	NULL
3	NULL
and	NULL
5	NULL
.	NULL

RNA	NULL
Isolation	NULL
and	NULL
Northern	NULL
Analysis-Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
THP-1	NULL
cells	NULL
using	NULL
TRIZOL	NULL
reagent	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
and	NULL
from	NULL
HUVECs	NULL
by	NULL
phenol	NULL
extraction	NULL
as	NULL
described	NULL
(	NULL
82	NULL
)	NULL
.	NULL

10	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
was	NULL
fractionated	NULL
on	NULL
a	NULL
1.2	NULL
%	NULL
agarose-formaldehyde	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
GeneScreen	NULL
membrane	NULL
(	NULL
DuPont	NULL
NEN	NULL
)	NULL
.	NULL

Membranes	NULL
were	NULL
hybridized	NULL
with	NULL
various	NULL
cDNA	NULL
fragments	NULL
labeled	NULL
with	NULL
[	NULL
«	NULL
-*	NULL
``	NULL
P	NULL
]	NULL
4CTP	NULL
(	NULL
>	NULL
3000	NULL
Ci/	NULL
mmol	NULL
;	NULL
ICN	NULL
,	NULL
Costa	NULL
Mesa	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
the	NULL
Prime-It	NULL
kit	NULL
II	NULL
(	NULL
Stratagene	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

TNFa	NULL
and	NULL
TF	NULL
cDNA	NULL
fragments	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
.	NULL

An	NULL
E-selectin	NULL
cDNA	NULL
fragment	NULL
was	NULL
obtained	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
,	NULL
and	NULL
a	NULL
1.3-kilobase	NULL
VCAM-1	NULL
cDNA	NULL
fragment	NULL
was	NULL
obtained	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

A	NULL
c-fos	NULL
cDNA	NULL
fragment	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
.	NULL

I.	NULL
Verma	NULL
(	NULL
Salk	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Variations	NULL
in	NULL
RNA	NULL
loadings	NULL
were	NULL
assessed	NULL
by	NULL
reprobing	NULL
filters	NULL
with	NULL
a	NULL
housekeeping	NULL
gene	NULL
,	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
,	NULL
obtained	NULL
from	NULL
Clontech	NULL
(	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Autoradiography	NULL
was	NULL
performed	NULL
at	NULL
-70	NULL
°C	NULL
using	NULL
Kodak	NULL
X-Omat	NULL
film	NULL
.	NULL

Nuclear	NULL
Run-on-Nuclear	NULL
run-on	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Prehybridization	NULL
,	NULL
hybridization	NULL
,	NULL
and	NULL
washing	NULL
of	NULL
the	NULL
filters	NULL
were	NULL
performed	NULL
using	NULL
a	NULL
TNFa	NULL
cDNA	NULL
fragment	NULL
;	NULL
a	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
cDNA	NULL
fragment	NULL
(	NULL
Clontech	NULL
)	NULL
;	NULL
and	NULL
a	NULL
vector	NULL
control	NULL
,	NULL
pSP73	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

Radioactivity	NULL
was	NULL
quantified	NULL
using	NULL
a	NULL
PhosphorImager	NULL
and	NULL
ImageQuant	NULL
software	NULL
(	NULL
Molecular	NULL
Dynam-ics	NULL
,	NULL
Inc.	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Plasmid	NULL
Constructions-pUHG10.3CAT	NULL
contains	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
cDNA	NULL
(	NULL
21	NULL
)	NULL
and	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
R.	NULL
Hooft	NULL
van	NULL
Huijsduijnen	NULL
(	NULL
Glaxo	NULL
Institute	NULL
for	NULL
Molecular	NULL
Biology	NULL
,	NULL
Ge-neva	NULL
,	NULL
Switzerland	NULL
)	NULL
.	NULL

pBasic-tet/VP16	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
the	NULL
cDNA	NULL
for	NULL
the	NULL
tetracycline	NULL
repressor/VP16	NULL
fusion	NULL
protein	NULL
and	NULL
the	NULL
B-glo-bin	NULL
intron/splice	NULL
sequence	NULL
into	NULL
the	NULL
BamHI/PsfI	NULL
and	NULL
NotI	NULL
sites	NULL
of	NULL
pBlue-script	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
DNA	NULL
fragments	NULL
were	NULL
amplified	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
from	NULL
pUHG15.1	NULL
as	NULL
described	NULL
(	NULL
21	NULL
)	NULL
using	NULL
primers	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
R.	NULL
Hooft	NULL
van	NULL
Huijsduijnen	NULL
.	NULL

pTF-tet/VP16	NULL
was	NULL
made	NULL
by	NULL
inserting	NULL
the	NULL
human	NULL
TF	NULL
promoter	NULL
(	NULL
-278	NULL
to	NULL
+121	NULL
base	NULL
pairs	NULL
)	NULL
into	NULL
the	NULL
EcoRU/HindIII	NULL
sites	NULL
of	NULL
pBasic-tet/VP16	NULL
.	NULL

pSV40-tet/VP16	NULL
was	NULL
created	NULL
by	NULL
cloning	NULL
the	NULL
minimal	NULL
SV40	NULL
promoter	NULL
from	NULL
the	NULL
pGL2	NULL
promoter	NULL
(	NULL
Promega	NULL
Corp.	NULL
)	NULL
into	NULL
the	NULL
KpnUHindIII	NULL
sites	NULL
of	NULL
pBasic-tet/VP16	NULL
.	NULL

p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
tet/VP16	NULL
and	NULL
p	NULL
(	NULL
«	NULL
B-1	NULL
)	NULL
,	NULL
-tet/VP16	NULL
contain	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
TF-	NULL
«	NULL
B	NULL
site	NULL
(	NULL
34	NULL
)	NULL
and	NULL
the	NULL
murine	NULL
Igx-	NULL
«	NULL
B	NULL
site	NULL
,	NULL
respectively	NULL
,	NULL
cloned	NULL
upstream	NULL
of	NULL
a	NULL
minimal	NULL
SV40	NULL
promoter	NULL
in	NULL
pSV4O0-tet/VP16	NULL
.	NULL

pCMV-tet/VP16	NULL
(	NULL
also	NULL
known	NULL
as	NULL
pUHG15.1	NULL
)	NULL
(	NULL
21	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Promoter	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
cells	NULL
cotransfected	NULL
with	NULL
pBasic-tet/VP16	NULL
derivatives	NULL
and	NULL
pUHG10.3CAT	NULL
(	NULL
21	NULL
)	NULL
.	NULL

pCMVp65	NULL
expresses	NULL
p65	NULL
from	NULL
a	NULL
cytomegalovirus	NULL
promoter	NULL
and	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
C.	NULL
Kunsch	NULL
(	NULL
Human	NULL
Genome	NULL
Sciences	NULL
,	NULL
Rockville	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

pRSVReIA	NULL
(	NULL
65	NULL
)	NULL
8276A	NULL
expresses	NULL
p65	NULL
containing	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
PKA	NULL
recognition	NULL
site	NULL
and	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
G.	NULL
Nabel	NULL
(	NULL
Howard	NULL
Hughes	NULL
Institute	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
.	NULL

pPKA	NULL
expresses	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
and	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
M.	NULL
Montminy	NULL
(	NULL
Salk	NULL
Institute	NULL
)	NULL
.	NULL

DNA	NULL
Transfection	NULL
and	NULL
CAT	NULL
Activity-THP-1	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
24	NULL
h	NULL
before	NULL
exposure	NULL
to	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

HUVECs	NULL
(	NULL
2	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
transfected	NULL
using	NULL
DEAE-dextran	NULL
as	NULL
described	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
24	NULL
h	NULL
before	NULL
exposure	NULL
to	NULL
TNFa	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
forskolin	NULL
(	NULL
50	NULL
uM	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
diffusion-based	NULL
assay	NULL
(	NULL
35	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
variations	NULL
in	NULL
transfection	NULL
efficien-cies	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
plasmid	NULL
pCMV	NULL
8	NULL
(	NULL
Clontech	NULL
)	NULL
,	NULL
which	NULL
expresses	NULL
the	NULL
LacZ	NULL
gene	NULL
.	NULL

Levels	NULL
of	NULL
B-galactosidase	NULL
were	NULL
determined	NULL
using	NULL
the	NULL
Galacto-Light	NULL
assay	NULL
system	NULL
(	NULL
Tropix	NULL
Inc.	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
exhibited	NULL
<	NULL
15	NULL
%	NULL
variation	NULL
between	NULL
samples	NULL
.	NULL

Nuclear	NULL
Extract	NULL
Preparation	NULL
and	NULL
Electrophoretic	NULL
Mobility	NULL
Shift	NULL
As-says-THP-1	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
in	NULL
the	NULL
20829	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
or	NULL
forskolin	NULL
(	NULL
50	NULL
um	NULL
)	NULL
.	NULL

HUVECs	NULL
were	NULL
stimulated	NULL
with	NULL
TNFa	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
forskolin	NULL
(	NULL
20-200	NULL
uM	NULL
)	NULL
.	NULL

Nuclear	NULL
extract	NULL
preparation	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
34	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Quantifica-tion	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Statistical	NULL
analysis	NULL
of	NULL
data	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
paired	NULL
Student	NULL
's	NULL
¢	NULL
test	NULL
.	NULL

Western	NULL
Blot	NULL
Analysis-IxBa	NULL
was	NULL
detected	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
from	NULL
THP-1	NULL
cells	NULL
and	NULL
HUVECs	NULL
as	NULL
described	NULL
(	NULL
11	NULL
,	NULL
37	NULL
)	NULL
using	NULL
a	NULL
1:500	NULL
dilution	NULL
of	NULL
an	NULL
anti-IxBa	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
was	NULL
monitored	NULL
by	NULL
Western	NULL
blotting	NULL
in	NULL
THP-1	NULL
cells	NULL
and	NULL
HUVECs	NULL
using	NULL
a	NULL
1:1000	NULL
dilution	NULL
of	NULL
an	NULL
anti-p65	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

In	NULL
Vivo	NULL
Labeling	NULL
of	NULL
Cells	NULL
and	NULL
Immunoprecipitation-Confluent	NULL
monolayers	NULL
of	NULL
HUVECs	NULL
in	NULL
10-cm	NULL
tissue	NULL
culture	NULL
dishes	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
and	NULL
incubated	NULL
in	NULL
phosphate-free	NULL
medium	NULL
containing	NULL
200	NULL
mCi	NULL
of	NULL
*°PO	NULL
,	NULL
/ml	NULL
(	NULL
400-800	NULL
mCi/ml	NULL
;	NULL
ICN	NULL
)	NULL
for	NULL
1	NULL
h.	NULL
Cells	NULL
were	NULL
stimulated	NULL
with	NULL
TNFa	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
for	NULL
1	NULL
h	NULL
with	NULL
or	NULL
without	NULL
a	NULL
20-min	NULL
pretreatment	NULL
with	NULL
forskolin	NULL
(	NULL
20	NULL
mM	NULL
)	NULL
.	NULL

After	NULL
incu-bation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
,	NULL
and	NULL
p65	NULL
was	NULL
recovered	NULL
by	NULL
immunoprecipitation	NULL
with	NULL
an	NULL
anti-p65	NULL
antibody	NULL
using	NULL
an	NULL
immunoprecipitation	NULL
kit	NULL
containing	NULL
protein	NULL
A	NULL
beads	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

The	NULL
precipitated	NULL
proteins	NULL
were	NULL
washed	NULL
several	NULL
times	NULL
,	NULL
eluted	NULL
in	NULL
sample	NULL
buffer	NULL
containing	NULL
25	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
separated	NULL
on	NULL
8-16	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
(	NULL
Novex	NULL
)	NULL
,	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

RESULTS	NULL
Elevated	NULL
cAMP	NULL
Inhibits	NULL
LPS	NULL
and	NULL
TNFa	NULL
Induction	NULL
of	NULL
a	NULL
Distinct	NULL
Set	NULL
of	NULL
Genes	NULL
in	NULL
Human	NULL
Monocytic	NULL
and	NULL
Endothelial	NULL
Cells-The	NULL
effect	NULL
of	NULL
elevated	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
on	NULL
LPS	NULL
induction	NULL
of	NULL
the	NULL
TF	NULL
and	NULL
TNFa	NULL
genes	NULL
in	NULL
human	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
was	NULL
investigated	NULL
using	NULL
Bt	NULL
,	NULL
cAMP	NULL
,	NULL
a	NULL
membrane-permeable	NULL
analog	NULL
of	NULL
cAMP	NULL
(	NULL
30	NULL
)	NULL
,	NULL
or	NULL
forskolin	NULL
,	NULL
an	NULL
activator	NULL
of	NULL
adenylyl	NULL
cyclase	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
reagent	NULL
concentration	NULL
used	NULL
in	NULL
this	NULL
study	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
increase	NULL
cAMP	NULL
levels	NULL
in	NULL
monocytes/macrophages	NULL
and	NULL
HUVECs	NULL
(	NULL
21	NULL
,	NULL
25	NULL
)	NULL
.	NULL

LPS	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
increased	NULL
the	NULL
steady-state	NULL
levels	NULL
of	NULL
TF	NULL
and	NULL
TNFa	NULL
mRNAs	NULL
at	NULL
2	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
immediately	NULL
before	NULL
LPS	NULL
stimulation	NULL
abolished	NULL
induction	NULL
of	NULL
TF	NULL
and	NULL
TNFa	NULL
mRNA	NULL
expression	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Bt	NULL
,	NULL
cAMP	NULL
reduced	NULL
TF	NULL
and	NULL
TNFa	NULL
mRNA	NULL
levels	NULL
in	NULL
unstimulated	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Bt	NULL
,	NULL
cAMP	NULL
induced	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
in	NULL
THP-1	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
Bt	NULL
,	NULL
cAMP	NULL
activates	NULL
PKA	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

TNFa	NULL
stimulation	NULL
of	NULL
HUVECs	NULL
increased	NULL
the	NULL
steady-state	NULL
levels	NULL
of	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
mRNAs	NULL
at	NULL
1	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
HUVECs	NULL
with	NULL
forskolin	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
TNFa	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
mRNAs	NULL
by	NULL
60	NULL
+	NULL
9	NULL
,	NULL
78	NULL
+	NULL
8	NULL
,	NULL
and	NULL
73	NULL
+	NULL
14	NULL
%	NULL
,	NULL
respectively	NULL
(	NULL
mean	NULL
*	NULL
S8.D	NULL
.	NULL

,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
forskolin	NULL
did	NULL
not	NULL
inhibit	NULL
TNFa	NULL
induction	NULL
of	NULL
ICAM-1	NULL
mRNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
previous	NULL
studies	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
agents	NULL
that	NULL
increase	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
by	NULL
two	NULL
independent	NULL
mechanisms	NULL
inhibit	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
distinct	NULL
set	NULL
of	NULL
genes	NULL
in	NULL
human	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
.	NULL

Elevated	NULL
cAMP	NULL
Inhibits	NULL
LPS	NULL
Induction	NULL
of	NULL
TNFa	NULL
Gene	NULL
Transcription	NULL
in	NULL
Monocytic	NULL
Cells-We	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
Bta	NULL
,	NULL
cAMP	NULL
on	NULL
LPS-induced	NULL
TNFa	NULL
gene	NULL
transcription	NULL
in	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
using	NULL
nuclear	NULL
run-on	NULL
assays	NULL
.	NULL

LPS	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
increased	NULL
the	NULL
rate	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
TNFa	NULL
gene	NULL
by	NULL
11.7-fold	NULL
at	NULL
1	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
Bt	NULL
,	NULL
cAMP	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
LPS	NULL
abolished	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
rate	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
TNFa	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
cAMP	NULL
inhibition	NULL
of	NULL
transcription	NULL
may	NULL
account	NULL
for	NULL
most	NULL
,	NULL
if	NULL
not	NULL
all	NULL
,	NULL
of	NULL
the	NULL
observed	NULL
inhibition	NULL
of	NULL
LPS-induced	NULL
TNFa	NULL
mRNA	NULL
expression	NULL
.	NULL

Elevated	NULL
cAMP	NULL
Inhibits	NULL
TNFa	NULL
Induction	NULL
of	NULL
TF	NULL
Promoter	NULL
Activity	NULL
in	NULL
Endothelial	NULL
Cells-The	NULL
human	NULL
TF	NULL
promoter	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
was	NULL
used	NULL
as	NULL
a	NULL
model	NULL
system	NULL
to	NULL
examine	NULL
inhibition	NULL
of	NULL
promoter	NULL
activity	NULL
in	NULL
THP-1	NULL
cells	NULL
and	NULL
HUVECs	NULL
by	NULL
Bt	NULL
,	NULL
cAMP	NULL
and	NULL
forskolin	NULL
.	NULL

These	NULL
studies	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
20830	NULL
A	NULL
THP	NULL
LPS	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Elevated	NULL
cAMP	NULL
in	NULL
THP-1	NULL
and	NULL
dbcAMP	NULL
HUVECs	NULL
inhibits	NULL
the	NULL
induction	NULL
of	NULL
TF	NULL
,	NULL
TNFa	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
mRNA	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
THP-1	NULL
cells	NULL
exposed	NULL
to	NULL
LPS	NULL
(	NULL
10	NULL
ug/	NULL
mRNA	NULL
ml	NULL
)	NULL
for	NULL
2	NULL
h	NULL
with	NULL
or	NULL
without	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
dbcAMP	NULL
;	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

B	NULL
,	NULL
total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
HUVECs	NULL
exposed	NULL
to	NULL
TNFa	NULL
(	NULL
20	NULL
ng/	NULL
ml	NULL
)	NULL
for	NULL
1	NULL
h	NULL
with	NULL
or	NULL
without	NULL
a	NULL
20-min	NULL
forskolin	NULL
pretreatment	NULL
(	NULL
Fsk	NULL
;	NULL
100	NULL
um	NULL
)	NULL
.	NULL

TF	NULL
,	NULL
TNFa	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
mRNA	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
B	NULL
HUVEC	NULL
analysis	NULL
using	NULL
the	NULL
appropriate	NULL
radiola-	NULL
TNFa	NULL
beled	NULL
human	NULL
cDNA	NULL
probes	NULL
.	NULL

Blots	NULL
were	NULL
Esk	NULL
reprobed	NULL
to	NULL
determine	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GSPDFH	NULL
)	NULL
mRNA	NULL
levels	NULL
as	NULL
a	NULL
measure	NULL
of	NULL
RNA	NULL
loading	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

mRNA	NULL
-	NULL
»	NULL
<	NULL
i	NULL
Wh	NULL
nes	NULL
«	NULL
hin	NULL
LPS	NULL
-	NULL
+	NULL
+	NULL
dbcAMP	NULL
-	NULL
-	NULL
+	NULL
vector	NULL
-	NULL
>	NULL
TNFo	NULL
.	NULL

-	NULL
>	NULL
.	NULL

«	NULL
se	NULL
‘	NULL
.	NULL

«	NULL
mes	NULL
G3PDH	NULL
-	NULL
>	NULL
nom	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Elevated	NULL
cAMP	NULL
inhibits	NULL
LPS-induced	NULL
TNFa	NULL
gene	NULL
transcription	NULL
.	NULL

Nuclei	NULL
were	NULL
isolated	NULL
from	NULL
unstimulated	NULL
THP-1	NULL
cells	NULL
,	NULL
cells	NULL
stimulated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
!	NULL
)	NULL

for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
cells	NULL
treated	NULL
with	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
dbcAMP	NULL
;	NULL
1	NULL
mM	NULL
)	NULL
before	NULL
LPS	NULL
stimulation	NULL
.	NULL

Labeled	NULL
nuclear	NULL
RNA	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
hybridization	NULL
to	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
G3PDH	NULL
)	NULL
and	NULL
TNFa	NULL
cDNAs	NULL
and	NULL
a	NULL
vector	NULL
control	NULL
(	NULL
pSP73	NULL
)	NULL
.	NULL

The	NULL
autoradiogram	NULL
was	NULL
exposed	NULL
for	NULL
12	NULL
days	NULL
at	NULL
-80	NULL
°C	NULL
with	NULL
an	NULL
intensifier	NULL
screen	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

indicated	NULL
that	NULL
Bt	NULL
;	NULL
cAMP	NULL
alone	NULL
induced	NULL
TF	NULL
promoter	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
plasmids	NULL
contain	NULL
cryptic	NULL
CRE	NULL
sites	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cAMP	NULL
and	NULL
cAMP	NULL
derivatives	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
luciferase	NULL
assay	NULL
(	NULL
38	NULL
)	NULL
.	NULL

There-fore	NULL
,	NULL
we	NULL
employed	NULL
a	NULL
two-plasmid	NULL
reporter	NULL
system	NULL
in	NULL
which	NULL
the	NULL
first	NULL
plasmid	NULL
contained	NULL
the	NULL
human	NULL
TF	NULL
promoter	NULL
expressing	NULL
a	NULL
tet/VP16	NULL
transcription	NULL
factor	NULL
that	NULL
transactivates	NULL
a	NULL
promoter	NULL
driving	NULL
expression	NULL
of	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
present	NULL
on	NULL
a	NULL
second	NULL
plasmid	NULL
,	NULL
pUHG10.3CAT	NULL
(	NULL
21	NULL
)	NULL
.	NULL

This	NULL
two-plasmid	NULL
reporter	NULL
system	NULL
had	NULL
two	NULL
advantages	NULL
:	NULL
(	NULL
i	NULL
)	NULL
pUHG10.3CAT	NULL
has	NULL
been	NULL
shown	NULL
not	NULL
to	NULL
contain	NULL
any	NULL
cryptic	NULL
CRE	NULL
sites	NULL
that	NULL
influence	NULL
expression	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
21	NULL
)	NULL
;	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
it	NULL
can	NULL
be	NULL
used	NULL
to	NULL
study	NULL
weak	NULL
promoters	NULL
,	NULL
such	NULL
as	NULL
the	NULL
TF	NULL
promoter	NULL
,	NULL
because	NULL
the	NULL
promoter	NULL
activity	NULL
is	NULL
amplified	NULL
by	NULL
expression	NULL
of	NULL
the	NULL
tet/VP16	NULL
transcription	NULL
factor	NULL
.	NULL

TF	NULL
promoter	NULL
activity	NULL
was	NULL
increased	NULL
by	NULL
4.3	NULL
+	NULL
1.1-fold	NULL
(	NULL
mean	NULL
*+	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
by	NULL
TNFa	NULL
stimulation	NULL
in	NULL
transiently	NULL
transfected	NULL
HUVECs	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
forskolin	NULL
before	NULL
TNFa	NULL
stimulation	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
TF	NULL
promoter	NULL
activity	NULL
by	NULL
44	NULL
+	NULL
3	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

Forskolin	NULL
alone	NULL
did	NULL
not	NULL
significantly	NULL
affect	NULL
TF	NULL
promoter	NULL
activity	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
TNFa	NULL
or	NULL
forskolin	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
level	NULL
of	NULL
CAT	NULL
expression	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
promoterless	NULL
control	NULL
plasmid	NULL
pBasic-tet/VP16	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
strongly	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
promoter	NULL
activity	NULL
in	NULL
transiently	NULL
transfected	NULL
THP-1	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Functional	NULL
Analysis	NULL
of	NULL
NF-	NULL
«	NULL
B-mediated	NULL
Transcription	NULL
in	NULL
Monocytic	NULL
and	NULL
Endothelial	NULL
Cells-The	NULL
NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
inducible	NULL
ex	NULL
Tissue	NULL
Factor	NULL
-	NULL
»	NULL
-	NULL
»	NULL
oolee	NULL
__	NULL
__	NULL
__	NULL
_	NULL
Tissue	NULL
Factor	NULL
-	NULL
»	NULL
Cyclic	NULL
AMP	NULL
Inhibition	NULL
of	NULL
Transcription	NULL
-o	NULL
+	NULL
-	NULL
+	NULL
-o	NULL
40	NULL
-	NULL
+	NULL
-o	NULL
¥	NULL
-	NULL
+	NULL
#	NULL
-o-	NULL
4	NULL
+	NULL
-o-	NULL
40+	NULL
-o	NULL
-	NULL
40	NULL
%	NULL
'	NULL
c-fos	NULL
-	NULL
>	NULL
wo	NULL
mew	NULL
mRNA	NULL
i	NULL
:	NULL
-	NULL
epenenen	NULL
bad	NULL
TNFa	NULL
.	NULL

-	NULL
»	NULL
E	NULL
mRNA	NULL
GEPDH	NULL
-	NULL
»	NULL
«	NULL
e	NULL
can	NULL
-o	NULL
40	NULL
-	NULL
+	NULL
-o	NULL
+	NULL
-	NULL
+	NULL
-o	NULL
4	NULL
-	NULL
+	NULL
-o	NULL
-	NULL
#	NULL
+4	NULL
-o	NULL
-	NULL
+	NULL
o+	NULL
-o-	NULL
+o	NULL
+	NULL
E-selectin	NULL
-	NULL
»	NULL
VCAM-1	NULL
-	NULL
.	NULL

\-	NULL
@	NULL
win	NULL
e	NULL
es	NULL
mRNA	NULL
mRNA	NULL
teu	NULL
G3PDH	NULL
-	NULL
»	NULL
«	NULL
ae	NULL
«	NULL
we	NULL
«	NULL
me	NULL
«	NULL
ae	NULL
G3PDH	NULL
-	NULL
>	NULL
@	NULL
@	NULL
t	NULL
am	NULL
Fold	NULL
Induction	NULL
of	NULL
CAT	NULL
Activity	NULL
pBasic	NULL
pTF	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Elevated	NULL
cAMP	NULL
inhibits	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
TF	NULL
promoter	NULL
in	NULL
HUVECs	NULL
.	NULL

HUVECs	NULL
were	NULL
cotransfected	NULL
with	NULL
pBasic-tet/VP16	NULL
(	NULL
pBasic	NULL
;	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
pUHG10.3CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
or	NULL
with	NULL
pTF-tet/VP16	NULL
(	NULL
pTF	NULL
;	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
pUHG10.3CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
using	NULL
DEAE-dextran	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TNFa	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
with	NULL
or	NULL
without	NULL
a	NULL
20-min	NULL
pretreatment	NULL
with	NULL
forskolin	NULL
(	NULL
Fsk	NULL
;	NULL
50	NULL
uM	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
a	NULL
further	NULL
24	NULL
h	NULL
before	NULL
determining	NULL
CAT	NULL
activity	NULL
.	NULL

Results	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
assessed	NULL
using	NULL
pCMV	NULL
$	NULL
and	NULL
exhibited	NULL
<	NULL
15	NULL
%	NULL
variation	NULL
between	NULL
samples	NULL
.	NULL

pression	NULL
of	NULL
the	NULL
TF	NULL
,	NULL
TNFa	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
genes	NULL
(	NULL
12-15	NULL
)	NULL
.	NULL

Elevated	NULL
cAMP	NULL
may	NULL
inhibit	NULL
all	NULL
of	NULL
these	NULL
genes	NULL
by	NULL
a	NULL
common	NULL
mechanism	NULL
involving	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
elevation	NULL
of	NULL
cAMP	NULL
inhibited	NULL
NF-	NULL
«	NULL
B-mediated	NULL
induction	NULL
of	NULL
gene	NULL
transcription	NULL
,	NULL
THP-1	NULL
cells	NULL
and	NULL
HUVECs	NULL
were	NULL
transfected	NULL
with	NULL
pSV40-tet/VP16	NULL
or	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
,	NULL
which	NULL
contains	NULL
four	NULL
«	NULL
B	NULL
sites	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
SV40	NULL
promoter	NULL
.	NULL

LPS	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
transfected	NULL
with	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
resulted	NULL
in	NULL
a	NULL
5.0	NULL
+	NULL
0.7-fold	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
»	NULL
=	NULL
5	NULL
)	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
THP-1	NULL
cells	NULL
with	NULL
Bt	NULL
,	NULL
cAMP	NULL
before	NULL
LPS	NULL
stimulation	NULL
resulted	NULL
in	NULL
a	NULL
61	NULL
*+	NULL
5	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
»	NULL
=	NULL
5	NULL
)	NULL
inhibition	NULL
of	NULL
LPS-induced	NULL
CAT	NULL
activity	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
using	NULL
a	NULL
plasmid	NULL
containing	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
murine	NULL
Igx-	NULL
«	NULL
B	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

No	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
THP-1	NULL
cells	NULL
transfected	NULL
with	NULL
pSV40-tet/VP16	NULL
,	NULL
which	NULL
contains	NULL
only	NULL
the	NULL
minimal	NULL
SV40	NULL
promoter	NULL
.	NULL

In	NULL
HUVECs	NULL
,	NULL
TNFa	NULL
induced	NULL
a	NULL
11.4	NULL
+	NULL
2.3-fold	NULL
(	NULL
mean	NULL
*	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
,	NULL
whereas	NULL
no	NULL
induction	NULL
was	NULL
observed	NULL
with	NULL
cells	NULL
transfected	NULL
with	NULL
pSV40-tet/VP16	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
HUVECs	NULL
with	NULL
forskolin	NULL
resulted	NULL
in	NULL
a	NULL
61	NULL
+	NULL
10	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
inhibition	NULL
of	NULL
TNFa-induced	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Cyclic	NULL
AMP	NULL
Inhibition	NULL
of	NULL
Transcription	NULL
THP-1	NULL
A	NULL
I	NULL
Fold	NULL
Induction	NULL
of	NULL
CAT	NULL
Activity	NULL
to	NULL
|	NULL
a-	NULL
T	NULL
1_l	NULL
_	NULL
I—	NULL
-o-	NULL
-	NULL
=	NULL
+o	NULL
+	NULL
=	NULL
=	NULL
+o	NULL
o+	NULL
Fo	NULL
O	NULL
ace	NULL
15	NULL
>	NULL
B	NULL
HUVEC	NULL
3	NULL
I	NULL
6	NULL
<	NULL
&	NULL
10	NULL
0	NULL
6	NULL
C	NULL
2	NULL
$	NULL
5	NULL
T	NULL
C	NULL
£	NULL
C	NULL
6	NULL
LL	NULL
0	NULL
TNFa	NULL
-	NULL
0	NULL
=	NULL
0	NULL
#	NULL
0	NULL
#	NULL
00	NULL
=o	NULL
=o	NULL
#	NULL
+	NULL
#	NULL
Fsk	NULL
04	NULL
o-	NULL
|	NULL
=o	NULL
$	NULL
00	NULL
-	NULL
04	NULL
%	NULL
pSV40	NULL
p	NULL
(	NULL
xB	NULL
)	NULL
4	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Elevated	NULL
cAMP	NULL
inhibits	NULL
NF-	NULL
«	NULL
B-mediated	NULL
gene	NULL
transcription	NULL
in	NULL
THP-1	NULL
cells	NULL
and	NULL
HUVECs	NULL
.	NULL

A	NULL
,	NULL
pSV40-tet/VP16	NULL
(	NULL
pSV40	NULL
;	NULL
5	NULL
ug	NULL
)	NULL
or	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
tet/VP16	NULL
(	NULL
p	NULL
(	NULL
xB	NULL
)	NULL
,	NULL
,	NULL
;	NULL
5	NULL
ug	NULL
)	NULL
was	NULL
cotransfected	NULL
with	NULL
pUHG10.3CAT	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
into	NULL
THP-1	NULL
cells	NULL
using	NULL
DEAE-dextran	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
divided	NULL
in	NULL
four	NULL
equal	NULL
portions	NULL
and	NULL
exposed	NULL
to	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
dbeAMP	NULL
;	NULL
1	NULL
mM	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

B	NULL
,	NULL
HUVECs	NULL
were	NULL
cotransfected	NULL
with	NULL
pSV40-tet/VP16	NULL
(	NULL
pSV40	NULL
;	NULL
10	NULL
ug	NULL
)	NULL
or	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
(	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
;	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
pUHG10.3CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TNFa	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
with	NULL
or	NULL
without	NULL
a	NULL
20-min	NULL
pretreatment	NULL
with	NULL
forskolin	NULL
(	NULL
sk	NULL
;	NULL
50	NULL
uM	NULL
)	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
assessed	NULL
using	NULL
pCMV	NULL
$	NULL
B	NULL
and	NULL
exhibited	NULL
<	NULL
15	NULL
%	NULL
variation	NULL
between	NULL
samples	NULL
.	NULL

Results	NULL
from	NULL
five	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
agents	NULL
that	NULL
elevate	NULL
cAMP	NULL
strongly	NULL
inhibit	NULL
NF-	NULL
«	NULL
B-mediated	NULL
gene	NULL
transcription	NULL
in	NULL
human	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
.	NULL

Nuclear	NULL
Translocation	NULL
of	NULL
NF-kB	NULL
/	NULL
Rel	NULL
Proteins	NULL
Is	NULL
Not	NULL
Affected	NULL
by	NULL
Elevated	NULL
cAMP-Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
may	NULL
be	NULL
due	NULL
to	NULL
a	NULL
block	NULL
in	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
and/or	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
these	NULL
proteins	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
on	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
these	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
a	NULL
«	NULL
kB	NULL
site	NULL
from	NULL
the	NULL
murine	NULL
Igx	NULL
enhancer	NULL
,	NULL
which	NULL
binds	NULL
p50/p65	NULL
heterodimers	NULL
,	NULL
and	NULL
a	NULL
«	NULL
B	NULL
site	NULL
from	NULL
the	NULL
human	NULL
TF	NULL
gene	NULL
,	NULL
which	NULL
binds	NULL
c-Rel/p65	NULL
heterodimers	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Previous	NULL
competition	NULL
and	NULL
antibody	NULL
supershift	NULL
experiments	NULL
have	NULL
established	NULL
the	NULL
protein	NULL
composition	NULL
of	NULL
these	NULL
complexes	NULL
(	NULL
11	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
these	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
THP-1	NULL
cells	NULL
was	NULL
examined	NULL
1	NULL
h	NULL
after	NULL
stimulation	NULL
because	NULL
the	NULL
maximal	NULL
rate	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
TF	NULL
and	NULL
TNFa	NULL
genes	NULL
was	NULL
previously	NULL
shown	NULL
to	NULL
occur	NULL
1	NULL
h	NULL
after	NULL
LPS	NULL
stimulation	NULL
(	NULL
8	NULL
,	NULL
5	NULL
)	NULL
.	NULL

LPS	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
for	NULL
1	NULL
h	NULL
induced	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p50/p65	NULL
and	NULL
c-Rel/p65	NULL
heterodimers	NULL
that	NULL
bound	NULL
the	NULL
Igk-	NULL
«	NULL
B	NULL
and	NULL
TF-	NULL
«	NULL
B	NULL
sites	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

No	NULL
statistically	NULL
20831	NULL
A	NULL
THP	NULL
LPS	NULL
-	NULL
$	NULL
-	NULL
+	NULL
-	NULL
o	NULL
>	NULL
+	NULL
dbcAMP	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-	NULL
+	NULL
+	NULL
pst/pes-	NULL
-	NULL
Wil	NULL
-	NULL
-	NULL
c-ReVp6S	NULL
-	NULL
a	NULL
H	NULL
ind	NULL
taal	NULL
bea	NULL
TNFa	NULL
-	NULL
#	NULL
-	NULL
+	NULL
-	NULL
+	NULL
Fsk	NULL
-	NULL
-	NULL
+	NULL
+	NULL
B	NULL
HUVEC	NULL
-	NULL
4	NULL
-	NULL
-	NULL
40+	NULL
we	NULL
pS0/pes	NULL
-	NULL
_	NULL
Wi	NULL
H	NULL
c-Rel/pés	NULL
-	NULL
®	NULL
Uh	NULL
“	NULL
Fic	NULL
.	NULL

5.	NULL
cAMP	NULL
does	NULL
not	NULL
inhibit	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
in	NULL
THP-1	NULL
cells	NULL
or	NULL
HUVECs	NULL
.	NULL

A	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
THP-1	NULL
cells	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
dbeAMP	NULL
;	NULL
1	NULL
mM	NULL
)	NULL
or	NULL
forskolin	NULL
(	NULL
Fsk	NULL
;	NULL
50	NULL
um	NULL
)	NULL
.	NULL

B	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
HUVECs	NULL
stimulated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
TNFa	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
with	NULL
or	NULL
without	NULL
a	NULL
20-min	NULL
pretreatment	NULL
with	NULL
forskolin	NULL
(	NULL
100	NULL
pM	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
p50/p65	NULL
and	NULL
c-Rel/p65	NULL
heterodimers	NULL
was	NULL
determined	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
using	NULL
radiolabeled	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
murine	NULL
Igx-	NULL
«	NULL
B	NULL
site	NULL
and	NULL
TF-	NULL
«	NULL
B	NULL
site	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
faster	NULL
migrating	NULL
band	NULL
represents	NULL
nonspecific	NULL
protein	NULL
binding	NULL
(	NULL
84	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

significant	NULL
differences	NULL
were	NULL
observed	NULL
between	NULL
the	NULL
levels	NULL
of	NULL
p50/65	NULL
(	NULL
p	NULL
<	NULL
0.49	NULL
)	NULL
and	NULL
c-Rel/p65	NULL
(	NULL
p	NULL
<	NULL
0.20	NULL
)	NULL
heterodimers	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
LPS	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
Nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
THP-1	NULL
cells	NULL
and	NULL
Bt	NULL
,	NULL
cAMP-treated	NULL
cells	NULL
showed	NULL
no	NULL
binding	NULL
of	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

The	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
genes	NULL
are	NULL
rapidly	NULL
and	NULL
transiently	NULL
expressed	NULL
in	NULL
endothelial	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
HUVECs	NULL
was	NULL
examined	NULL
1	NULL
h	NULL
after	NULL
stimulation	NULL
because	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
is	NULL
increased	NULL
at	NULL
this	NULL
time	NULL
(	NULL
11	NULL
,	NULL
17	NULL
)	NULL
.	NULL

TNFa	NULL
stimulation	NULL
of	NULL
HUVECs	NULL
induced	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p50/p65	NULL
and	NULL
c-Rel/p65	NULL
heterodimers	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
forskolin	NULL
to	NULL
HUVECs	NULL
before	NULL
TNFa	NULL
stimulation	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p50/p65	NULL
and	NULL
c-Rel/p65	NULL
heterodimers	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

No	NULL
statistically	NULL
significant	NULL
differences	NULL
were	NULL
observed	NULL
between	NULL
the	NULL
levels	NULL
of	NULL
p50/p65	NULL
(	NULL
p	NULL
<	NULL
0.44	NULL
)	NULL
and	NULL
c-Rel/p65	NULL
(	NULL
p	NULL
<	NULL
0.14	NULL
)	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
TNFa	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
forskolin	NULL
.	NULL

Forskolin	NULL
alone	NULL
did	NULL
not	NULL
induce	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
in	NULL
HUVECs	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
forskolin	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p50/p65	NULL
induced	NULL
by	NULL
LPS	NULL
stimulation	NULL
of	NULL
HUVECs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Antibody	NULL
supershift	NULL
experiments	NULL
indicated	NULL
that	NULL
elevated	NULL
cAMP	NULL
did	NULL
not	NULL
change	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
p50/p65	NULL
and	NULL
c-Rel/p65	NULL
het-erodimeric	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
antibody	NULL
supershift	NULL
experiments	NULL
using	NULL
an	NULL
anti-CREB	NULL
antibody	NULL
excluded	NULL
the	NULL
possibility	NULL
that	NULL
elevation	NULL
of	NULL
cAMP	NULL
induced	NULL
binding	NULL
of	NULL
CREB	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Bt	NULL
,	NULL
cAMP	NULL
and	NULL
forskolin	NULL
do	NULL
not	NULL
affect	NULL
either	NULL
the	NULL
nuclear	NULL
translocation	NULL
or	NULL
DNA	NULL
binding	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
Rel	NULL
complexes	NULL
in	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
20832	NULL
A	NULL
mp1	NULL
Cytosolic	NULL
_	NULL
Nuclear	NULL
rpg	NULL
LPS	NULL
-	NULL
+	NULL
-	NULL
#	NULL
-	NULL
+	NULL
-	NULL
+	NULL
dbcAMP	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-	NULL
-	NULL
+	NULL
+	NULL
kD	NULL
rse	NULL
--	NULL
--	NULL
-	NULL
-:3	NULL
-	NULL
50	NULL
-	NULL
36	NULL
~	NULL
30	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
pB	NULL
Huvec	NULL
TNFa	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Esk	NULL
(	NULL
LM	NULL
)	NULL
-	NULL
-	NULL
20	NULL
50	NULL
100200	NULL
kD	NULL
-64	NULL
LcBo	NULL
:	NULL
-	NULL
«	NULL
lll	NULL
mes	NULL
aas	NULL
aas	NULL
eae	NULL
as	NULL
~50	NULL
i	NULL
-36	NULL
Inn	NULL
im	NULL
mn	NULL
mm	NULL
onl	NULL
~	NULL
30	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Elevated	NULL
cAMP	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
or	NULL
proteolysis	NULL
of	NULL
IxBa	NULL
.	NULL

A	NULL
,	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
THP-1	NULL
cells	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
dbeAMP	NULL
;	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

p65	NULL
levels	NULL
in	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
determined	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
a	NULL
1:1000	NULL
dilution	NULL
of	NULL
a	NULL
specific	NULL
anti-p65	NULL
antibody	NULL
.	NULL

B	NULL
,	NULL
cytosolic	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
HUVECs	NULL
pretreated	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
forskolin	NULL
(	NULL
Fsk	NULL
;	NULL
20-200	NULL
um	NULL
)	NULL
for	NULL
20	NULL
min	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
TNFa	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
15	NULL
min	NULL
.	NULL

I	NULL
«	NULL
Ba	NULL
protein	NULL
levels	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
were	NULL
determined	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
a	NULL
1:500	NULL
dilution	NULL
of	NULL
an	NULL
anti-I	NULL
«	NULL
Ba	NULL
antibody	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
elevated	NULL
cAMP	NULL
did	NULL
not	NULL
selectively	NULL
inhibit	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
,	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
THP-1	NULL
cells	NULL
were	NULL
examined	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
a	NULL
p65-specific	NULL
antibody	NULL
.	NULL

LPS	NULL
stimulation	NULL
induced	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
Bt	NULL
,	NULL
cAMP	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
.	NULL

Similarly	NULL
,	NULL
preincubation	NULL
of	NULL
HUVECs	NULL
for	NULL
20	NULL
min	NULL
with	NULL
forskolin	NULL
(	NULL
20	NULL
mx	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
TNFa-induced	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
at	NULL
15	NULL
min	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
elevated	NULL
cAMP	NULL
affected	NULL
IxBa	NULL
proteolysis	NULL
,	NULL
IxBa	NULL
levels	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
from	NULL
HUVECs	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

TNFa	NULL
induced	NULL
the	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
forskolin	NULL
(	NULL
20-200	NULL
um	NULL
)	NULL
did	NULL
not	NULL
significantly	NULL
reduce	NULL
the	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IkxBa	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
Bt	NULL
,	NULL
cAMP	NULL
(	NULL
1	NULL
mym	NULL
)	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
in	NULL
THP-1	NULL
cells	NULL
stimulated	NULL
with	NULL
LPS	NULL
for	NULL
1	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TNFa-induced	NULL
Phosphorylation	NULL
of	NULL
p65	NULL
Is	NULL
Not	NULL
Affected	NULL
by	NULL
Elevated	NULL
cAMP-A	NULL
recent	NULL
study	NULL
showed	NULL
that	NULL
p65	NULL
is	NULL
strongly	NULL
phosphorylated	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
in	NULL
vivo	NULL
(	NULL
39	NULL
)	NULL
.	NULL

More	NULL
detailed	NULL
studies	NULL
indicated	NULL
that	NULL
p65	NULL
contains	NULL
two	NULL
transactivation	NULL
(	NULL
TA	NULL
)	NULL
domains	NULL
in	NULL
the	NULL
carboxyl-terminal	NULL
end	NULL
(	NULL
40	NULL
)	NULL
.	NULL

TAq	NULL
is	NULL
constitutively	NULL
phosphorylated	NULL
,	NULL
whereas	NULL
stimulation	NULL
of	NULL
cells	NULL
induces	NULL
phosphorylation	NULL
of	NULL
TA	NULL
;	NULL
and	NULL
is	NULL
correlated	NULL
with	NULL
increased	NULL
transcriptional	NULL
activity	NULL
(	NULL
40	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
elevated	NULL
cAMP	NULL
inhibited	NULL
the	NULL
functional	NULL
activity	NULL
of	NULL
nuclear	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
by	NULL
modifying	NULL
the	NULL
phosphorylation	NULL
of	NULL
p65	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
phosphorylation	NULL
of	NULL
p65	NULL
in	NULL
TNFa-stimulated	NULL
HUVECs	NULL
with	NULL
or	NULL
without	NULL
forskolin	NULL
.	NULL

p65	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
unlabeled	NULL
HUVECs	NULL
and	NULL
detected	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
an	NULL
anti-p65	NULL
antibody	NULL
to	NULL
confirm	NULL
selective	NULL
recovery	NULL
of	NULL
p65	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
p65	NULL
was	NULL
prevented	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
peptide	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
that	NULL
was	NULL
used	NULL
to	NULL
raise	NULL
the	NULL
antibody	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TNFa	NULL
induced	NULL
a	NULL
strong	NULL
phosphorylation	NULL
of	NULL
p65	NULL
in	NULL
HUVECs	NULL
,	NULL
which	NULL
was	NULL
not	NULL
Cyclic	NULL
AMP	NULL
Inhibition	NULL
of	NULL
Transcription	NULL
TNFa	NULL
-	NULL
-	NULL
+4	NULL
+	NULL
#	NULL
Fsk	NULL
Lq	NULL
,	NULL
-	NULL
4	NULL
kD	NULL
-	NULL
250	NULL
hoist	NULL
wham	NULL
o	NULL
-	NULL
98	NULL
péS	NULL
+	NULL
waa	NULL
coe	NULL
_	NULL
-	NULL
G4	NULL
-	NULL
50	NULL
t	NULL
ie	NULL
-	NULL
30	NULL
1	NULL
20	NULL
3	NULL
4	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

TNFa-induced	NULL
phosphorylation	NULL
of	NULL
p65	NULL
in	NULL
HUVECs	NULL
.	NULL

Phosphate-labeled	NULL
HUVECs	NULL
were	NULL
stimulated	NULL
with	NULL
TNFa	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
1	NULL
h	NULL
with	NULL
or	NULL
without	NULL
a	NULL
20-min	NULL
pretreatment	NULL
with	NULL
forskolin	NULL
(	NULL
Fsk	NULL
;	NULL
20	NULL
um	NULL
)	NULL
.	NULL

Phosphorylated	NULL
p65	NULL
was	NULL
recovered	NULL
by	NULL
immunoprecipitation	NULL
and	NULL
analyzed	NULL
on	NULL
an	NULL
8-16	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
,	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
an	NULL
independent	NULL
experiment	NULL
.	NULL

affected	NULL
by	NULL
pretreatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
forskolin	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

A	NULL
low	NULL
constitutive	NULL
phosphorylation	NULL
of	NULL
p65	NULL
was	NULL
observed	NULL
in	NULL
unstimulated	NULL
HUVECs	NULL
,	NULL
which	NULL
was	NULL
not	NULL
increased	NULL
by	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
forskolin	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Additional	NULL
phosphorylated	NULL
proteins	NULL
observed	NULL
in	NULL
these	NULL
studies	NULL
may	NULL
represent	NULL
commu-noprecipitation	NULL
of	NULL
other	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
associated	NULL
with	NULL
p65	NULL
as	NULL
shown	NULL
previously	NULL
(	NULL
39	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
activation	NULL
of	NULL
PKA	NULL
does	NULL
not	NULL
modify	NULL
the	NULL
TNFa	NULL
«	NULL
-induced	NULL
phosphorylation	NULL
of	NULL
p65	NULL
,	NULL
although	NULL
we	NULL
can	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
forskolin	NULL
changes	NULL
the	NULL
sites	NULL
of	NULL
phosphorylation	NULL
of	NULL
p65	NULL
.	NULL

NF-kB-mediated	NULL
Transcription	NULL
Is	NULL
Inhibited	NULL
by	NULL
Elevated	NULL
cAMP	NULL
and	NULL
by	NULL
Activation	NULL
of	NULL
PKA-The	NULL
effect	NULL
of	NULL
increased	NULL
levels	NULL
of	NULL
intracellular	NULL
cAMP	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
on	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
was	NULL
measured	NULL
in	NULL
HUVECs	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
,	NULL
pUHG10.3CAT	NULL
,	NULL
and	NULL
pCMVp65	NULL
.	NULL

Expression	NULL
of	NULL
p65	NULL
increased	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
by	NULL
22.1	NULL
+	NULL
1.3-fold	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
,	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
control	NULL
plasmid	NULL
,	NULL
pSV40-tet/VP16	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Forskolin	NULL
reduced	NULL
the	NULL
level	NULL
of	NULL
p65	NULL
transactivation	NULL
by	NULL
74	NULL
+	NULL
10	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
forskolin	NULL
nonspecifically	NULL
reduced	NULL
transcription	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
,	NULL
which	NULL
was	NULL
used	NULL
to	NULL
express	NULL
p65	NULL
,	NULL
we	NULL
determined	NULL
CAT	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
forskolin	NULL
in	NULL
HUVECs	NULL
transfected	NULL
with	NULL
pCMV-tet/	NULL
VP16	NULL
,	NULL
which	NULL
expresses	NULL
the	NULL
tet/VP16	NULL
transcription	NULL
factor	NULL
from	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
.	NULL

Forskolin	NULL
did	NULL
not	NULL
affect	NULL
cytomegalovirus	NULL
promoter	NULL
activity	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
activation	NULL
of	NULL
PKA	NULL
was	NULL
required	NULL
to	NULL
inhibit	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
TNFa	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
HUVECs	NULL
overexpressing	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
.	NULL

HUVECs	NULL
were	NULL
cotransfected	NULL
with	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/	NULL
VP16	NULL
,	NULL
pUHG10.3CAT	NULL
,	NULL
and	NULL
pPKA	NULL
,	NULL
which	NULL
expresses	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
.	NULL

Expression	NULL
of	NULL
PKA	NULL
inhibited	NULL
the	NULL
TNFa	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
by	NULL
69	NULL
+	NULL
8	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
activation	NULL
of	NULL
PKA	NULL
inhibited	NULL
p65	NULL
transactivation	NULL
,	NULL
HUVECs	NULL
were	NULL
cotransfected	NULL
with	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
,	NULL
pUHG10.3CAT	NULL
,	NULL
and	NULL
pCMVp65	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
pPKA	NULL
.	NULL

p65	NULL
transactivation	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
by	NULL
coexpression	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
maximal	NULL
levels	NULL
of	NULL
PKA	NULL
inhibited	NULL
p65	NULL
transactivation	NULL
by	NULL
75	NULL
+	NULL
10	NULL
%	NULL
(	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

,	NULL
n	NULL
»	NULL
=	NULL
3	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
activation	NULL
of	NULL
PKA	NULL
either	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
or	NULL
by	NULL
expression	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
inhibits	NULL
transcription	NULL
mediated	NULL
by	NULL
endogenous	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
or	NULL
by	NULL
overexpressed	NULL
p65	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Cyclic	NULL
AMP	NULL
Inhibition	NULL
of	NULL
Transcription	NULL
20833	NULL
25	NULL
2	NULL
A	NULL
T	NULL
2	NULL
3	NULL
24	NULL
i	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

NF-	NULL
«	NULL
B-mediated	NULL
transcrip-	NULL
g	NULL
tion	NULL
and	NULL
p65	NULL
transactivation	NULL
activity	NULL
w	NULL
0	NULL
15	NULL
7	NULL
are	NULL
inhibited	NULL
by	NULL
elevated	NULL
cAMP	NULL
and	NULL
g	NULL
PKA	NULL
.	NULL

A	NULL
,	NULL
HUVECs	NULL
were	NULL
cotransfected	NULL
with	NULL
.o	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
tet/VP16	NULL
(	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
,	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
‘	NULL
g	NULL
’	NULL
10	NULL
pUHG10.3CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
or	NULL
with	NULL
p	NULL
(	NULL
xB	NULL
)	NULL
,	NULL
-tet/	NULL
C	NULL
VP16	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
pUHG10.3CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
-	NULL
T	NULL
pCMVp65	NULL
(	NULL
p65	NULL
;	NULL
5	NULL
ug	NULL
)	NULL
.	NULL

The	NULL
total	NULL
amount	NULL
of	NULL
g	NULL
&	NULL
plasmid	NULL
in	NULL
each	NULL
transfection	NULL
was	NULL
equalized	NULL
tL	NULL
to	NULL
25	NULL
ug	NULL
using	NULL
pUC18	NULL
DNA	NULL
.	NULL

Forskolin	NULL
(	NULL
Fisk	NULL
;	NULL
50	NULL
pM	NULL
)	NULL
was	NULL
added	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
o	NULL
_	NULL
a	NULL
-	NULL
|___	NULL
M	NULL
___I	NULL
and	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
a	NULL
further	NULL
24	NULL
h	NULL
p6és	NULL
-	NULL
L	NULL
+	NULL
+	NULL
L	NULL
L	NULL
before	NULL
determining	NULL
CAT	NULL
activity	NULL
.	NULL

HUVECs	NULL
were	NULL
cotransfected	NULL
with	NULL
pCMV-tet/VP16	NULL
Fsk	NULL
-	NULL
*+	NULL
~	NULL
*+	NULL
~	NULL
*+	NULL
(	NULL
pCMV	NULL
;	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
pUHG10.3	NULL
CAT	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
.	NULL

l	NULL
|	NULL
|	NULL
|	NULL
After	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
forskolin	NULL
(	NULL
50	NULL
uM	NULL
)	NULL
for	NULL
a	NULL
p	NULL
(	NULL
xB	NULL
)	NULL
4	NULL
pCMmVv	NULL
further	NULL
24	NULL
h.	NULL
Results	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

B	NULL
,	NULL
HUVECs	NULL
2	NULL
20	NULL
&	NULL
15	NULL
were	NULL
cotransfected	NULL
with	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
tet/VP16	NULL
3	NULL
2	NULL
C	NULL
(	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
,	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
pUHG10.3CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
<	NULL
3	NULL
with	NULL
or	NULL
without	NULL
pPKA	NULL
(	NULL
PKA	NULL
;	NULL
10	NULL
ug	NULL
)	NULL
.	NULL

After	NULL
k	NULL
i-24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TNFa	NULL
(	NULL
20	NULL
3	NULL
3	NULL
10	NULL
ng/ml	NULL
)	NULL
for	NULL
24	NULL
h.	NULL
C	NULL
,	NULL
HUVECs	NULL
were	NULL
cotrans-	NULL
5	NULL
a-fected	NULL
with	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-tet/VP16	NULL
(	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
,	NULL
;	NULL
5	NULL
ug	NULL
)	NULL
,	NULL
2	NULL
19	NULL
g	NULL
pUHG10.3CAT	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
,	NULL
pCMVp65	NULL
(	NULL
p65	NULL
;	NULL
2	NULL
0	NULL
0	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
5	NULL
or	NULL
10	NULL
ug	NULL
of	NULL
pPKA	NULL
(	NULL
PKA	NULL
)	NULL
as	NULL
indi-	NULL
S	NULL
§	NULL
s	NULL
cated	NULL
.	NULL

The	NULL
total	NULL
amount	NULL
of	NULL
plasmid	NULL
in	NULL
each	NULL
3	NULL
5	NULL
G	NULL
transfection	NULL
was	NULL
adjusted	NULL
to	NULL
30	NULL
ug	NULL
using	NULL
~	NULL
£	NULL
pUC18	NULL
DNA	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
g	NULL
g	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

t	NULL
-	NULL
o	NULL
iL	NULL
TNFa	NULL
-	NULL
=	NULL
+	NULL
+	NULL
PKA	NULL
DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
activation	NULL
of	NULL
PKA	NULL
by	NULL
agents	NULL
that	NULL
elevate	NULL
cAMP	NULL
in	NULL
human	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
inhibited	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
distinct	NULL
set	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel-regulated	NULL
genes	NULL
,	NULL
including	NULL
TNF	NULL
«	NULL
,	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
.	NULL

A	NULL
common	NULL
inhibitory	NULL
mechanism	NULL
was	NULL
identified	NULL
that	NULL
involved	NULL
reduction	NULL
in	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
.	NULL

Our	NULL
studies	NULL
demonstrated	NULL
that	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
elevated	NULL
cAMP	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
forskolin	NULL
did	NULL
not	NULL
modify	NULL
the	NULL
TNFa-induced	NULL
phosphorylation	NULL
of	NULL
p65	NULL
.	NULL

However	NULL
,	NULL
transactivation	NULL
by	NULL
p65	NULL
was	NULL
inhibited	NULL
by	NULL
activation	NULL
of	NULL
endogenous	NULL
PKA	NULL
and	NULL
by	NULL
overexpression	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
activation	NULL
of	NULL
PKA	NULL
reduced	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
in	NULL
human	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
.	NULL

Our	NULL
studies	NULL
show	NULL
that	NULL
elevation	NULL
of	NULL
cAMP	NULL
by	NULL
both	NULL
Bt	NULL
,	NULL
cAMP	NULL
and	NULL
forskolin	NULL
inhibited	NULL
the	NULL
functional	NULL
activity	NULL
of	NULL
endogenous	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
in	NULL
human	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
also	NULL
showed	NULL
that	NULL
forskolin	NULL
inhibits	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
in	NULL
HUVECs	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
may	NULL
be	NULL
due	NULL
to	NULL
a	NULL
block	NULL
in	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
and/or	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
these	NULL
proteins	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
agents	NULL
that	NULL
elevate	NULL
cAMP	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

l	NULL
proteins	NULL
or	NULL
proteolytic	NULL
degradation	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
.	NULL

Similarly	NULL
,	NULL
two	NULL
recent	NULL
reports	NULL
indicated	NULL
that	NULL
forskolin	NULL
does	NULL
not	NULL
reduce	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
human	NULL
promyelocytic	NULL
HL-60	NULL
cells	NULL
and	NULL
HUVECs	NULL
(	NULL
21	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Forskolin	NULL
and	NULL
Bt	NULL
,	NULL
cAMP	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
or	NULL
induce	NULL
the	NULL
binding	NULL
of	NULL
CRE-binding	NULL
protein	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Instead	NULL
,	NULL
we	NULL
p	NULL
(	NULL
«	NULL
B	NULL
)	NULL
4	NULL
p	NULL
(	NULL
xB	NULL
)	NULL
4	NULL
demonstrated	NULL
that	NULL
elevation	NULL
of	NULL
cAMP	NULL
or	NULL
expression	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
strongly	NULL
inhibited	NULL
transcription	NULL
mediated	NULL
by	NULL
endogenous	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
and	NULL
overexpressed	NULL
p65	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
using	NULL
Jurkat	NULL
T-cells	NULL
suggested	NULL
that	NULL
cAMP	NULL
inhibition	NULL
of	NULL
interleukin-2	NULL
gene	NULL
expression	NULL
is	NULL
due	NULL
to	NULL
a	NULL
small	NULL
change	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
,	NULL
which	NULL
selectively	NULL
decreases	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
(	NULL
42	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
p65	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
affected	NULL
40	NULL
min	NULL
after	NULL
stimulation	NULL
,	NULL
which	NULL
is	NULL
similar	NULL
to	NULL
our	NULL
studies	NULL
using	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
(	NULL
Figs	NULL
.	NULL

5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
and	NULL
only	NULL
a	NULL
small	NULL
change	NULL
was	NULL
noted	NULL
2	NULL
h	NULL
after	NULL
stimulation	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Functional	NULL
studies	NULL
using	NULL
a	NULL
chimeric	NULL
Gal4-p65	NULL
protein	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
transactivation	NULL
domain	NULL
of	NULL
p65	NULL
,	NULL
indicated	NULL
that	NULL
forskolin	NULL
did	NULL
not	NULL
inhibit	NULL
transactivation	NULL
by	NULL
Gal4-p65	NULL
in	NULL
human	NULL
E14	NULL
T	NULL
lymphoma	NULL
cells	NULL
(	NULL
42	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
use	NULL
of	NULL
Gal4-binding	NULL
sites	NULL
and	NULL
a	NULL
chimeric	NULL
protein	NULL
in	NULL
place	NULL
of	NULL
«	NULL
B-binding	NULL
sites	NULL
and	NULL
wild-type	NULL
p65	NULL
may	NULL
not	NULL
recapitulate	NULL
cAMP-mediated	NULL
inhi-bition	NULL
.	NULL

The	NULL
use	NULL
of	NULL
different	NULL
cell	NULL
types	NULL
may	NULL
account	NULL
for	NULL
these	NULL
different	NULL
inhibitory	NULL
mechanisms	NULL
.	NULL

Alternatively	NULL
,	NULL
costimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
and	NULL
E14	NULL
T-cells	NULL
with	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomy-cin	NULL
rather	NULL
than	NULL
LPS	NULL
or	NULL
cytokines	NULL
may	NULL
explain	NULL
these	NULL
differences	NULL
.	NULL

Our	NULL
study	NULL
and	NULL
those	NULL
of	NULL
others	NULL
(	NULL
21	NULL
,	NULL
22	NULL
,	NULL
25	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
elevated	NULL
cAMP	NULL
in	NULL
monocytes/macrophages	NULL
and	NULL
endothelial	NULL
cells	NULL
selectively	NULL
inhibits	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
distinct	NULL
set	NULL
of	NULL
genes	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
elevated	NULL
cAMP	NULL
does	NULL
not	NULL
inhibit	NULL
other	NULL
inducible	NULL
genes	NULL
such	NULL
as	NULL
ICAM-1	NULL
and	NULL
interleukin-1	NULL
(	NULL
21	NULL
,	NULL
22	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Interest-ingly	NULL
,	NULL
induction	NULL
of	NULL
the	NULL
ICAM-1	NULL
gene	NULL
in	NULL
endothelial	NULL
cells	NULL
is	NULL
regulated	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
by	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
(	NULL
17	NULL
)	NULL
.	NULL

However	NULL
,	NULL
inhibition	NULL
of	NULL
TNFa-induced	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
HUVECs	NULL
by	NULL
aspirin	NULL
reduces	NULL
VCAM-1	NULL
and	NULL
E-selectin	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
20834	NULL
expression	NULL
without	NULL
affecting	NULL
ICAM-1	NULL
expression	NULL
(	NULL
43	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
unlike	NULL
VCAM-1	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
TF	NULL
,	NULL
ICAM-1	NULL
is	NULL
constitutively	NULL
expressed	NULL
by	NULL
HUVECs	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
ICAM-1	NULL
is	NULL
delayed	NULL
compared	NULL
with	NULL
these	NULL
other	NULL
genes	NULL
(	NULL
17	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
ICAM-1	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
different	NULL
combination	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Elevated	NULL
cAMP	NULL
may	NULL
also	NULL
regulate	NULL
the	NULL
activity	NULL
of	NULL
other	NULL
transcription	NULL
factors	NULL
that	NULL
are	NULL
required	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
TNFa	NULL
,	NULL
TF	NULL
,	NULL
E-selectin	NULL
,	NULL
and	NULL
VCAM-1	NULL
genes	NULL
.	NULL

In	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
,	NULL
Bt	NULL
,	NULL
cAMP	NULL
abolished	NULL
LPS	NULL
induction	NULL
of	NULL
TNFa	NULL
and	NULL
TF	NULL
mRNA	NULL
expression	NULL
and	NULL
TNFa	NULL
gene	NULL
transcription	NULL
,	NULL
but	NULL
only	NULL
partially	NULL
inhibited	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
in	NULL
transfected	NULL
cells	NULL
,	NULL
suggesting	NULL
the	NULL
possibility	NULL
that	NULL
cAMP	NULL
may	NULL
inhibit	NULL
other	NULL
transcription	NULL
factors	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
composition	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
CRE/ATF	NULL
site	NULL
in	NULL
the	NULL
E-selectin	NULL
promoter	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
contribute	NULL
to	NULL
the	NULL
cAMP	NULL
inhibition	NULL
of	NULL
the	NULL
E-selectin	NULL
gene	NULL
in	NULL
bovine	NULL
aortic	NULL
endothelial	NULL
cells	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
TNFa	NULL
and	NULL
TF	NULL
promoters	NULL
contain	NULL
AP-1	NULL
sites	NULL
that	NULL
contribute	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
these	NULL
genes	NULL
(	NULL
13	NULL
,	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

We	NULL
can	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
elevated	NULL
cAMP	NULL
may	NULL
,	NULL
in	NULL
part	NULL
,	NULL
reduce	NULL
TNFa	NULL
and	NULL
TF	NULL
gene	NULL
transcription	NULL
by	NULL
modulating	NULL
protein	NULL
binding	NULL
to	NULL
these	NULL
AP-1	NULL
sites	NULL
and/or	NULL
by	NULL
inhibiting	NULL
AP-1	NULL
activity	NULL
.	NULL

Our	NULL
preliminary	NULL
studies	NULL
indicate	NULL
that	NULL
cAMP	NULL
increases	NULL
protein	NULL
binding	NULL
to	NULL
both	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
TF	NULL
promoter	NULL
,	NULL
but	NULL
so	NULL
far	NULL
,	NULL
no	NULL
changes	NULL
in	NULL
protein	NULL
composition	NULL
have	NULL
been	NULL
detected	NULL
.	NULL
``	NULL

Further	NULL
studies	NULL
are	NULL
required	NULL
to	NULL
determine	NULL
if	NULL
cAMP	NULL
inhibits	NULL
expression	NULL
of	NULL
this	NULL
distinct	NULL
set	NULL
of	NULL
genes	NULL
via	NULL
multiple	NULL
mechanisms	NULL
.	NULL

PKA	NULL
can	NULL
modulate	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
number	NULL
of	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
(	NULL
47	NULL
)	NULL
.	NULL

In	NULL
yeast	NULL
,	NULL
the	NULL
PKA-dependent	NULL
phosphorylation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
ADR1	NULL
inactivates	NULL
its	NULL
transcriptional	NULL
activity	NULL
without	NULL
altering	NULL
its	NULL
binding	NULL
to	NULL
DNA	NULL
(	NULL
48	NULL
,	NULL
49	NULL
)	NULL
.	NULL

In	NULL
our	NULL
studies	NULL
,	NULL
PKA	NULL
may	NULL
directly	NULL
phosphorylate	NULL
p65	NULL
or	NULL
initiate	NULL
a	NULL
signaling	NULL
cascade	NULL
involving	NULL
other	NULL
kinases	NULL
that	NULL
reduce	NULL
the	NULL
functional	NULL
activity	NULL
of	NULL
NF-	NULL
«	NULL
B-Rel	NULL
complexes	NULL
.	NULL

Indeed	NULL
,	NULL
c-Rel	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
p50	NULL
all	NULL
contain	NULL
a	NULL
conserved	NULL
serine	NULL
in	NULL
a	NULL
consensus	NULL
PKA	NULL
recognition	NULL
site	NULL
(	NULL
X-Arg-Arg-X-Ser-X	NULL
)	NULL
near	NULL
the	NULL
carboxyl-terminal	NULL
end	NULL
of	NULL
the	NULL
ref	NULL
homology	NULL
domain	NULL
(	NULL
50	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
role	NULL
of	NULL
this	NULL
PKA	NULL
site	NULL
is	NULL
unclear	NULL
because	NULL
it	NULL
is	NULL
not	NULL
present	NULL
in	NULL
all	NULL
NF-	NULL
«	NULL
B/	NULL
Rel	NULL
proteins	NULL
.	NULL

Mutation	NULL
of	NULL
serine	NULL
266	NULL
to	NULL
alanine	NULL
in	NULL
c-Rel	NULL
reduces	NULL
DNA	NULL
binding	NULL
and	NULL
transactivation	NULL
,	NULL
suggesting	NULL
that	NULL
serine	NULL
266	NULL
contributes	NULL
to	NULL
protein	NULL
dimerization	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
mutation	NULL
of	NULL
serine	NULL
276	NULL
to	NULL
alanine	NULL
in	NULL
p65	NULL
abolished	NULL
its	NULL
transactivation	NULL
activity	NULL
in	NULL
HUVECs	NULL
,	NULL
making	NULL
it	NULL
impossible	NULL
to	NULL
determine	NULL
if	NULL
elevated	NULL
cAMP	NULL
inhibited	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
by	NULL
direct	NULL
phosphorylation	NULL
of	NULL
the	NULL
consensus	NULL
PKA	NULL
site	NULL
of	NULL
p65	NULL
.	NULL
``	NULL

Phorbol	NULL
ester-dependent	NULL
phosphorylation	NULL
of	NULL
the	NULL
TAs	NULL
transactivation	NULL
domain	NULL
of	NULL
p65	NULL
enhances	NULL
its	NULL
transactivating	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
phorbol	NULL
ester-activated	NULL
protein	NULL
kinase	NULL
C	NULL
directly	NULL
phosphorylates	NULL
TA	NULL
;	NULL
on	NULL
serine	NULL
residues	NULL
(	NULL
40	NULL
)	NULL
.	NULL

We	NULL
showed	NULL
that	NULL
forskolin	NULL
did	NULL
not	NULL
modify	NULL
the	NULL
TNFa-induced	NULL
phosphorylation	NULL
of	NULL
nuclear	NULL
p65	NULL
in	NULL
HUVECs	NULL
.	NULL

However	NULL
,	NULL
changes	NULL
in	NULL
the	NULL
phosphorylation	NULL
pattern	NULL
of	NULL
p65	NULL
would	NULL
not	NULL
be	NULL
detected	NULL
in	NULL
this	NULL
experiment	NULL
.	NULL

PKA	NULL
may	NULL
modulate	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
by	NULL
phosphorylating	NULL
cofactors	NULL
that	NULL
are	NULL
required	NULL
for	NULL
transactivation	NULL
.	NULL

Alternatively	NULL
,	NULL
cAMP	NULL
may	NULL
induce	NULL
the	NULL
synthesis	NULL
or	NULL
activation	NULL
of	NULL
transcriptional	NULL
inhibitors	NULL
of	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
such	NULL
as	NULL
Bel3	NULL
(	NULL
51	NULL
,	NULL
52	NULL
)	NULL
and	NULL
p202	NULL
,	NULL
which	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
enhancers	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
PKA	NULL
signaling	NULL
pathway	NULL
may	NULL
inhibit	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
by	NULL
squelching	NULL
coactivators	NULL
.	NULL

Pharmacologic	NULL
agents	NULL
that	NULL
elevate	NULL
cellular	NULL
levels	NULL
of	NULL
cAMP	NULL
,	NULL
such	NULL
as	NULL
pentoxifylline	NULL
and	NULL
rolipram	NULL
,	NULL
have	NULL
been	NULL
observed	NULL
to	NULL
inhibit	NULL
LPS-induced	NULL
TNFa	NULL
and	NULL
TF	NULL
gene	NULL
transcription	NULL
in	NULL
mono	NULL
2	NULL
V.	NULL
Ollivier	NULL
and	NULL
N.	NULL
Mackman	NULL
,	NULL
unpublished	NULL
data	NULL
.	NULL

°	NULL
G.	NULL
C.	NULL
N.	NULL
Parry	NULL
and	NULL
N.	NULL
Mackman	NULL
,	NULL
unpublished	NULL
data	NULL
.	NULL

Cyclic	NULL
AMP	NULL
Inhibition	NULL
of	NULL
Transcription	NULL
cytes	NULL
in	NULL
vitro	NULL
(	NULL
27	NULL
,	NULL
54	NULL
,	NULL
55	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
pentoxifylline	NULL
markedly	NULL
inhibits	NULL
increases	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
TNFa	NULL
and	NULL
TF	NULL
in	NULL
vivo	NULL
in	NULL
a	NULL
chimpanzee	NULL
model	NULL
of	NULL
endotoxemia	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Other	NULL
drugs	NULL
such	NULL
as	NULL
rolipram	NULL
and	NULL
amrinone	NULL
suppress	NULL
T-cell	NULL
activation	NULL
in	NULL
vitro	NULL
and	NULL
may	NULL
be	NULL
beneficial	NULL
agents	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
autoimmune	NULL
en-cephalomyelitis	NULL
and	NULL
acute	NULL
cardiac	NULL
allographt	NULL
rejection	NULL
(	NULL
57	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
elevation	NULL
of	NULL
cellular	NULL
cAMP	NULL
in	NULL
vivo	NULL
may	NULL
reduce	NULL
induction	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
inflammation	NULL
associated	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
diseases	NULL
.	NULL

Acknowledgments-We	NULL
acknowledge	NULL
Dr.	NULL
R.	NULL
Hooft	NULL
van	NULL
Huijsduijnen	NULL
for	NULL
providing	NULL
pUHG10.3CAT	NULL
,	NULL
pUHG15.1	NULL
,	NULL
and	NULL
polymerase	NULL
chain	NULL
reaction	NULL
primers	NULL
;	NULL
Dr.	NULL
C.	NULL
Kunsch	NULL
for	NULL
pCMVp65	NULL
;	NULL
Dr.	NULL
G.	NULL
Nabel	NULL
for	NULL
pRSVReIA	NULL
(	NULL
65	NULL
)	NULL
8276A	NULL
;	NULL
Dr.	NULL
M.	NULL
Montminy	NULL
for	NULL
pPKA	NULL
;	NULL
Drs	NULL
.	NULL

M.	NULL
Read	NULL
and	NULL
T.	NULL
Collins	NULL
(	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
an	NULL
ICAM-1	NULL
cDNA	NULL
fragment	NULL
;	NULL
Dr	NULL
.	NULL

I.	NULL
Verma	NULL
for	NULL
a	NULL
c-fos	NULL
cDNA	NULL
fragment	NULL
;	NULL
Dr.	NULL
A.	NULL
Bier-haus	NULL
(	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Technical	NULL
University	NULL
of	NULL
Dresden	NULL
,	NULL
Dresden	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
advice	NULL
on	NULL
Western	NULL
blotting	NULL
;	NULL
Dr.	NULL
E.	NULL
Levin	NULL
(	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
advice	NULL
on	NULL
phosphate	NULL
labeling	NULL
of	NULL
endothelial	NULL
cells	NULL
;	NULL
M.	NULL
Smith	NULL
,	NULL
H.	NULL
McClary	NULL
,	NULL
and	NULL
Y.	NULL
Ko	NULL
for	NULL
technical	NULL
assistance	NULL
;	NULL
Drs	NULL
.	NULL

A.	NULL
McLachlan	NULL
and	NULL
L.	NULL
Curtiss	NULL
for	NULL
helpful	NULL
suggestions	NULL
;	NULL
Dr.	NULL
T.	NULL
S.	NULL
Edgington	NULL
for	NULL
support	NULL
;	NULL
and	NULL
J.	NULL
Robertson	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Miiller	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Ziegler-Heitbrock	NULL
,	NULL
H.	NULL
W.	NULL
L.	NULL
,	NULL
and	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Immu-nobiology	NULL
187	NULL
,	NULL
283-256	NULL
2	NULL
.	NULL

Collins	NULL
,	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
Lab	NULL
.	NULL

Invest	NULL
.	NULL

68	NULL
,	NULL
499-508	NULL
3	NULL
.	NULL

Burchett	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Weaver	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Westall	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Larsen	NULL
,	NULL
A.	NULL
,	NULL
Kronheim	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Wilson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
3473-3481	NULL
4	NULL
.	NULL

Gregory	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Morrissey	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Edgington	NULL
,	NULL
T.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9	NULL
,	NULL
2752-2755	NULL
5	NULL
.	NULL

Brand	NULL
,	NULL
K.	NULL
,	NULL
Fowler	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Edgington	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
and	NULL
Mackman	NULL
,	NULL
N.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
4732-4738	NULL
6	NULL
.	NULL

Montgomery	NULL
,	NULL
K.	NULL
F.	NULL
,	NULL
Osborn	NULL
,	NULL
L.	NULL
,	NULL
Hession	NULL
,	NULL
C.	NULL
,	NULL
Tizard	NULL
,	NULL
R.	NULL
,	NULL
Goff	NULL
,	NULL
D.	NULL
,	NULL
Vassallo	NULL
,	NULL
C.	NULL
,	NULL
Tarr	NULL
,	NULL
P.	NULL
I.	NULL
,	NULL
Bomsztyk	NULL
,	NULL
K.	NULL
,	NULL
Lobb	NULL
,	NULL
R.	NULL
,	NULL
Harlan	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Pohlman	NULL
,	NULL
T.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
65283-6527	NULL
7.	NULL
van	NULL
de	NULL
Stolpe	NULL
,	NULL
A.	NULL
,	NULL
Caldenhoven	NULL
,	NULL
E.	NULL
,	NULL
Stade	NULL
,	NULL
B.	NULL
G.	NULL
,	NULL
Koenderman	NULL
,	NULL
L.	NULL
,	NULL
Raaijmakers	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
M.	NULL
,	NULL
Johnson	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
van	NULL
der	NULL
Saag	NULL
,	NULL
P.	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
6185-6192	NULL
8	NULL
.	NULL

Tademarco	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
McQuillan	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Rosen	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
and	NULL
Dean	NULL
,	NULL
D.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
16323-16329	NULL
9	NULL
.	NULL

Scarpati	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Sadler	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
20705-20713	NULL
10	NULL
.	NULL

Crossman	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Carr	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Tuddenham	NULL
,	NULL
E.	NULL
G.	NULL
D.	NULL
,	NULL
Pearson	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
McVey	NULL
,	NULL
J.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
9782-9787	NULL
11	NULL
.	NULL

Parry	NULL
,	NULL
G.	NULL
C.	NULL
N.	NULL
,	NULL
and	NULL
Mackman	NULL
,	NULL
N.	NULL
(	NULL
1995	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

15	NULL
,	NULL
612-621	NULL
12	NULL
.	NULL

Ziegler-Heitbrock	NULL
,	NULL
H.	NULL
W.	NULL
L.	NULL
,	NULL
Sternsdorf	NULL
,	NULL
T.	NULL
,	NULL
Liese	NULL
,	NULL
J.	NULL
,	NULL
Belohradsky	NULL
,	NULL
B.	NULL
,	NULL
Weber	NULL
,	NULL
C.	NULL
,	NULL
Wedel	NULL
,	NULL
A.	NULL
,	NULL
Schreck	NULL
,	NULL
R.	NULL
,	NULL
B	NULL
&	NULL
uerle	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Strobel	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
6986-6993	NULL
13	NULL
.	NULL

Mackman	NULL
,	NULL
N.	NULL
,	NULL
Brand	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Edgington	NULL
,	NULL
T.	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174	NULL
,	NULL
1517-1526	NULL
14	NULL
.	NULL

Whitley	NULL
,	NULL
M.	NULL
Z.	NULL
,	NULL
Thanos	NULL
,	NULL
D.	NULL
,	NULL
Read	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Maniatis	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
6464-6475	NULL
15	NULL
.	NULL

Neish	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Read	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Thanos	NULL
,	NULL
D.	NULL
,	NULL
Pine	NULL
,	NULL
R.	NULL
,	NULL
Maniatis	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
2558-2569	NULL
16	NULL
.	NULL

Grilli	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
J.	NULL
J.-S.	NULL
,	NULL
and	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Int	NULL
.	NULL

Rev	NULL
.	NULL

Cytol	NULL
.	NULL

1-62	NULL
17	NULL
.	NULL

Collins	NULL
,	NULL
T.	NULL
,	NULL
Read	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Neish	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Whitley	NULL
,	NULL
M.	NULL
Z.	NULL
,	NULL
Thanos	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
FASEB	NULL
J	NULL
.	NULL

9	NULL
,	NULL
899-909	NULL
18	NULL
.	NULL

Mackman	NULL
,	NULL
N.	NULL
(	NULL
1995	NULL
)	NULL
FASEB	NULL
J	NULL
.	NULL

9	NULL
,	NULL
883-889	NULL
19	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
(	NULL
19983	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
2064-2070	NULL
20	NULL
.	NULL

Lalli	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
17359-17362	NULL
21	NULL
.	NULL

Ghersa	NULL
,	NULL
P.	NULL
,	NULL
Hooft	NULL
van	NULL
Huijsduijnen	NULL
,	NULL
R.	NULL
,	NULL
Whelan	NULL
,	NULL
J.	NULL
,	NULL
Cambet	NULL
,	NULL
Y.	NULL
,	NULL
Pescini	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
DeLamarter	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
29129-29137	NULL
22	NULL
.	NULL

Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Slowik	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
De	NULL
Luca	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
and	NULL
Ritchie	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

150	NULL
,	NULL
5114-5123	NULL
23	NULL
.	NULL

Taffet	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Singhel	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Overholtzer	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
and	NULL
Shurtleff	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Cell	NULL
.	NULL

Immunol	NULL
.	NULL

120	NULL
,	NULL
291-300	NULL
24	NULL
.	NULL

Crutchley	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
Hirsh	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Blood	NULL
78	NULL
,	NULL
382-386	NULL
25	NULL
.	NULL

Tannenbaum	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
and	NULL
Hamilton	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
1274-1280	NULL
26	NULL
.	NULL

Crutchley	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Solomon	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
Conanan	NULL
,	NULL
L.	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

12	NULL
,	NULL
664-670	NULL
27.	NULL
de	NULL
Prost	NULL
,	NULL
D.	NULL
,	NULL
Ollivier	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Hakim	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

88	NULL
,	NULL
562-566	NULL
28	NULL
.	NULL

Ollivier	NULL
,	NULL
V.	NULL
,	NULL
Ternisien	NULL
,	NULL
C.	NULL
,	NULL
Vu	NULL
,	NULL
T.	NULL
,	NULL
Hakim	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
de	NULL
Prost	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

822	NULL
,	NULL
231-234	NULL
29	NULL
.	NULL

Lyberg	NULL
,	NULL
T.	NULL
(	NULL
1983	NULL
)	NULL
Thromb	NULL
.	NULL

Haemostasis	NULL
50	NULL
,	NULL
804-809	NULL
30	NULL
.	NULL

Ollivier	NULL
,	NULL
V.	NULL
,	NULL
Houssaye	NULL
,	NULL
S.	NULL
,	NULL
Ternisien	NULL
,	NULL
C.	NULL
,	NULL
Léon	NULL
,	NULL
A.	NULL
,	NULL
de	NULL
Verneuil	NULL
,	NULL
H.	NULL
,	NULL
Elbim	NULL
,	NULL
C.	NULL
,	NULL
Mackman	NULL
,	NULL
N.	NULL
,	NULL
Edgington	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
and	NULL
de	NULL
Prost	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
81	NULL
,	NULL
973-979	NULL
31	NULL
.	NULL

Crutchley	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Conanan	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
Toledo	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Solomon	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
Que	NULL
,	NULL
B.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

18	NULL
,	NULL
1082-1089	NULL
32	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Sambrook	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
33	NULL
.	NULL

Oeth	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Mackman	NULL
,	NULL
N.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
86	NULL
,	NULL
4144-4152	NULL
34	NULL
.	NULL

Oeth	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Parry	NULL
,	NULL
G.	NULL
C.	NULL
N.	NULL
,	NULL
Kunsch	NULL
,	NULL
C.	NULL
,	NULL
Nantermet	NULL
,	NULL
P.	NULL
,	NULL
Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Mackman	NULL
,	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
3772-3781	NULL
35	NULL
.	NULL

Neumann	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Morency	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Russian	NULL
,	NULL
K.	NULL
O	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
BioTechniques	NULL
5	NULL
,	NULL
444-447	NULL
36	NULL
.	NULL

Cordle	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Donald	NULL
,	NULL
R.	NULL
,	NULL
Read	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Hawiger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
19983	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

Cyclic	NULL
AMP	NULL
Inhibition	NULL
268	NULL
,	NULL
11803-11810	NULL
Mackman	NULL
,	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
26363-26367	NULL
Benzakour	NULL
,	NULL
O.	NULL
,	NULL
Kanthou	NULL
,	NULL
C.	NULL
,	NULL
Dennehy	NULL
,	NULL
U.	NULL
,	NULL
Haq	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Berg	NULL
,	NULL
L.-P.	NULL
,	NULL
and	NULL
Kakkar	NULL
,	NULL
V.	NULL
V.	NULL
(	NULL
1995	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

809	NULL
,	NULL
385-387	NULL
Naumann	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Scheidereit	NULL
,	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

18	NULL
,	NULL
4597-4607	NULL
Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
dos	NULL
Santos	NULL
Silva	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
15576-15584	NULL
Hohmann	NULL
,	NULL
H.-P.	NULL
,	NULL
Kolbeck	NULL
,	NULL
R.	NULL
,	NULL
Remy	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
van	NULL
Loon	NULL
,	NULL
A.	NULL
P.	NULL
G.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
2315-2318	NULL
Neumann	NULL
,	NULL
M.	NULL
,	NULL
Grieshammer	NULL
,	NULL
T.	NULL
,	NULL
Chuypilo	NULL
,	NULL
S.	NULL
,	NULL
Kneitz	NULL
,	NULL
B.	NULL
,	NULL
Lohoff	NULL
,	NULL
M.	NULL
,	NULL
Schimpl	NULL
,	NULL
A.	NULL
,	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

14	NULL
,	NULL
1991-2004	NULL
Weber	NULL
,	NULL
C.	NULL
,	NULL
Erl	NULL
,	NULL
W.	NULL
,	NULL
Pietsch	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Weber	NULL
,	NULL
P.	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
Circulation	NULL
91	NULL
,	NULL
1914-1917	NULL
De	NULL
Luca	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
Johnson	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Whitley	NULL
,	NULL
M.	NULL
Z.	NULL
,	NULL
Collins	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
19193-19196	NULL
Newell	NULL
,	NULL
C.	NULL
,	NULL
Deisseroth	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Lopez-Berestein	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

56	NULL
,	NULL
27-35	NULL
Trede	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Teytsykova	NULL
,	NULL
A.	NULL
V.	NULL
,	NULL
Chatila	NULL
,	NULL
T.	NULL
,	NULL
Goldfeld	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
and	NULL
Geha	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

902-908	NULL
47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58.	NULL
of	NULL
Transcription	NULL
20835	NULL
Iyengar	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
271	NULL
,	NULL
461-463	NULL
Cherry	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Johnson	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
Dollard	NULL
,	NULL
C.	NULL
,	NULL
Shuster	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
and	NULL
Denis	NULL
,	NULL
C.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
56	NULL
,	NULL
409-419	NULL
Taylor	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
and	NULL
Young	NULL
,	NULL
E.	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
4098-4102	NULL
Mosialos	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Gilmore	NULL
,	NULL
T.	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Oncogene	NULL
8	NULL
,	NULL
721-730	NULL
Wulezyn	NULL
,	NULL
F.	NULL
G.	NULL
,	NULL
Naumann	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Scheidereit	NULL
,	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
858	NULL
,	NULL
597-599	NULL
Franzoso	NULL
,	NULL
G.	NULL
,	NULL
Bours	NULL
,	NULL
V.	NULL
,	NULL
Park	NULL
,	NULL
S.	NULL
,	NULL
Tomita-Yamaguchi	NULL
,	NULL
M.	NULL
,	NULL
Kelly	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
359	NULL
,	NULL
339-342	NULL
Min	NULL
,	NULL
W.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Lengyel	NULL
,	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
359-368	NULL
Han	NULL
,	NULL
J.	NULL
,	NULL
Thompson	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Beutler	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
391-394	NULL
Semmler	NULL
,	NULL
J.	NULL
,	NULL
Wachtel	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Endres	NULL
,	NULL
8	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Int	NULL
.	NULL

J.	NULL
Immunopharmacol	NULL
.	NULL

15	NULL
,	NULL
409-413	NULL
Taylor	NULL
,	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
NIH	NULL
Res	NULL
.	NULL

6	NULL
,	NULL
57-61	NULL
Hirozane	NULL
,	NULL
T.	NULL
,	NULL
Matsumori	NULL
,	NULL
A.	NULL
,	NULL
Furukawa	NULL
,	NULL
Y.	NULL
,	NULL
Matsui	NULL
,	NULL
S.	NULL
,	NULL
Sato	NULL
,	NULL
Y.	NULL
,	NULL
Matoba	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Sasayama	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

102	NULL
,	NULL
186-191	NULL
Sommer	NULL
,	NULL
N.	NULL
,	NULL
Loschmann	NULL
,	NULL
P.-A	NULL
.	NULL

,	NULL
Northoff	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Weller	NULL
,	NULL
M.	NULL
,	NULL
Steinbrecher	NULL
,	NULL
A.	NULL
,	NULL
Steinbach	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Lichtenfels	NULL
,	NULL
R.	NULL
,	NULL
Meyermann	NULL
,	NULL
R.	NULL
,	NULL
Riethmiiller	NULL
,	NULL
A.	NULL
,	NULL
Fontana	NULL
,	NULL
A.	NULL
,	NULL
Dichgans	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
Med	NULL
.	NULL

1	NULL
,	NULL
244-248	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Elevated	NULL
Cyclic	NULL
AMP	NULL
Inhibits	NULL
NF-xB-mediated	NULL
Transcription	NULL
in	NULL
Human	NULL
Monocytic	NULL
Cells	NULL
and	NULL
Endothelial	NULL
Cells	NULL
Veronique	NULL
Ollivier	NULL
,	NULL
Graham	NULL
C.	NULL
N.	NULL
Parry	NULL
,	NULL
Ronald	NULL
R.	NULL
Cobb	NULL
,	NULL
Dominique	NULL
de	NULL
Prost	NULL
and	NULL
Nigel	NULL
Mackman	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1996	NULL
,	NULL
271:20828-20835.	NULL
doi	NULL
:	NULL
10.1074/jb0.271.34.20828	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/271/34/20828	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
55	NULL
references	NULL
,	NULL
35	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
4q	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL

